Document:

Form of Subordinated Debt Indenture

 Exhibit 4.6 
 CELL THERAPEUTICS, INC. 
 Issuer 
 AND 
 [                                       
 ] 
 Trustee 
 INDENTURE

 Dated as of
[                        ] 
 Subordinated Debt Securities 

 TABLE OF CONTENTS 
  

							
	 	    	 	  	 	  	Page
	ARTICLE 1	  	DEFINITIONS	  	1
				
		    	Section 1.1	  	 Definitions of Terms
	  	1
			
	ARTICLE 2	  	ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES	  	4
				
		    	Section 2.1	  	 Designation and Terms of Securities
	  	4
				
		    	Section 2.2	  	 Form of Securities and Trustee’s Certificate
	  	6
				
		    	Section 2.3	  	 Denominations: Provisions for Payment
	  	6
				
		    	Section 2.4	  	 Execution and Authentications
	  	8
				
		    	Section 2.5	  	 Registration of Transfer and Exchange
	  	8
				
		    	Section 2.6	  	 Temporary Securities
	  	9
				
		    	Section 2.7	  	 Mutilated, Destroyed, Lost or Stolen Securities
	  	10
				
		    	Section 2.8	  	 Cancellation
	  	10
				
		    	Section 2.9	  	 Benefits of Indenture
	  	10
				
		    	Section 2.10	  	 Authenticating Agent
	  	11
				
		    	Section 2.11	  	 Global Securities
	  	11
			
	ARTICLE 3	  	REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS	  	12
				
		    	Section 3.1	  	 Redemption
	  	12
				
		    	Section 3.2	  	 Notice of Redemption
	  	12
				
		    	Section 3.3	  	 Payment Upon Redemption
	  	13
				
		    	Section 3.4	  	 Sinking Fund
	  	14
				
		    	Section 3.5	  	 Satisfaction of Sinking Fund Payments with Securities
	  	14
				
		    	Section 3.6	  	 Redemption of Securities for Sinking Fund
	  	14
			
	ARTICLE 4	  	COVENANTS	  	14
				
		    	Section 4.1	  	 Payment of Principal, Premium and Interest
	  	14
				
		    	Section 4.2	  	 Maintenance of Office or Agency
	  	15
				
		    	Section 4.3	  	 Paying Agents
	  	15
				
		    	Section 4.4	  	 Appointment to Fill Vacancy in Office of Trustee
	  	16
				
		    	Section 4.5	  	 Compliance with Consolidation Provisions
	  	16
			
	ARTICLE 5	  	SECURITYHOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE	  	16
				
		    	Section 5.1	  	 Company to Furnish Trustee Names and Addresses of Securityholders
	  	16
				
		    	Section 5.2	  	 Preservation Of Information; Communications With Securityholders
	  	17
				
		    	Section 5.3	  	 Reports by the Company
	  	17
				
		    	Section 5.4	  	 Reports by the Trustee
	  	17

  

 i 

 TABLE OF CONTENTS 
 (continued) 
  

							
	 	    	 	  	 	  	Page
	ARTICLE 6	  	REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT	  	17
				
		    	Section 6.1	  	 Events of Default
	  	17
				
		    	Section 6.2	  	 Collection of Indebtedness and Suits for Enforcement by Trustee
	  	19
				
		    	Section 6.3	  	 Application of Moneys Collected
	  	20
				
		    	Section 6.4	  	 Limitation on Suits
	  	21
				
		    	Section 6.5	  	 Rights and Remedies Cumulative; Delay or Omission Not Waiver
	  	21
				
		    	Section 6.6	  	 Control by Securityholders
	  	21
				
		    	Section 6.7	  	 Undertaking to Pay Costs
	  	22
			
	ARTICLE 7	  	CONCERNING THE TRUSTEE	  	22
				
		    	Section 7.1	  	 Certain Duties and Responsibilities of Trustee
	  	22
				
		    	Section 7.2	  	 Certain Rights of Trustee
	  	23
				
		    	Section 7.3	  	 Trustee Not Responsible for Recitals or Issuance or Securities
	  	24
				
		    	Section 7.4	  	 May Hold Securities
	  	25
				
		    	Section 7.5	  	 Moneys Held in Trust
	  	25
				
		    	Section 7.6	  	 Compensation and Reimbursement
	  	25
				
		    	Section 7.7	  	 Reliance on Officers’ Certificate
	  	25
				
		    	Section 7.8	  	 Section 7.8 Disqualification; Conflicting Interests
	  	26
				
		    	Section 7.9	  	 Corporate Trustee Required; Eligibility
	  	26
				
		    	Section 7.10	  	 Resignation and Removal; Appointment of Successor
	  	26
				
		    	Section 7.11	  	 Acceptance of Appointment By Successor
	  	27
				
		    	Section 7.12	  	 Merger, Conversion, Consolidation or Succession to Business
	  	28
				
		    	Section 7.13	  	 Preferential Collection of Claims Against the Company
	  	28
				
		    	Section 7.14	  	 Notice of Default
	  	29
			
	ARTICLE 8	  	CONCERNING THE SECURITYHOLDERS	  	29
				
		    	Section 8.1	  	 Evidence of Action by Securityholders
	  	29
				
		    	Section 8.2	  	 Proof of Execution by Securityholders
	  	29
				
		    	Section 8.3	  	 Who May be Deemed Owners
	  	30
				
		    	Section 8.4	  	 Certain Securities Owned by Company Disregarded
	  	30
				
		    	Section 8.5	  	 Actions Binding on Future Securityholders
	  	30
			
	ARTICLE 9	  	SUPPLEMENTAL INDENTURES	  	31
				
		    	Section 9.1	  	 Supplemental Indentures Without the Consent of Securityholders
	  	31

  

 ii 

 TABLE OF CONTENTS 
 (continued) 
  

							
	 	    	 	  	 	  	Page
		    	Section 9.2	  	 Supplemental Indentures With Consent of Securityholders
	  	32
				
		    	Section 9.3	  	 Effect of Supplemental Indentures
	  	32
				
		    	Section 9.4	  	 Securities Affected by Supplemental Indentures
	  	32
				
		    	Section 9.5	  	 Execution of Supplemental Indentures
	  	32
			
	ARTICLE 10	  	SUCCESSOR ENTITY	  	33
				
		    	Section 10.1	  	 Company May Consolidate, Etc
	  	33
				
		    	Section 10.2	  	 Successor Entity Substituted
	  	33
				
		    	Section 10.3	  	 Evidence of Consolidation, Etc. to Trustee
	  	34
			
	ARTICLE 11	  	SATISFACTION AND DISCHARGE	  	34
				
		    	Section 11.1	  	 Satisfaction and Discharge of Indenture
	  	34
				
		    	Section 11.2	  	 Discharge of Obligations
	  	34
				
		    	Section 11.3	  	 Deposited Moneys to be Held in Trust
	  	35
				
		    	Section 11.4	  	 Payment of Moneys Held by Paying Agents
	  	35
				
		    	Section 11.5	  	 Repayment to Company
	  	35
			
	ARTICLE 12	  	IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS	  	35
				
		    	Section 12.1	  	 No Recourse
	  	35
			
	ARTICLE 13	  	MISCELLANEOUS PROVISIONS	  	36
				
		    	Section 13.1	  	 Effect on Successors and Assigns
	  	36
				
		    	Section 13.2	  	 Actions by Successor
	  	36
				
		    	Section 13.3	  	 Surrender of Company Powers
	  	36
				
		    	Section 13.4	  	 Notices
	  	36
				
		    	Section 13.5	  	 Governing Law
	  	36
				
		    	Section 13.6	  	 Treatment of Securities as Debt
	  	37
				
		    	Section 13.7	  	 Compliance Certificates and Opinions
	  	37
				
		    	Section 13.8	  	 Payments on Business Days
	  	37
				
		    	Section 13.9	  	 Conflict with Trust Indenture Act
	  	37
				
		    	Section 13.10	  	 Counterparts
	  	37
				
		    	Section 13.11	  	 Separability
	  	37
				
		    	Section 13.12	  	 Compliance Certificates
	  	38
			
	ARTICLE 14	  	SUBORDINATION OF SECURITIES	  	38
				
		    	Section 14.1	  	 Subordination Terms
	  	38

  

 iii 

 INDENTURE 
 INDENTURE, dated as of [                        ], between Cell Therapeutics, Inc.,
a Washington corporation (the “Company”), and             , as trustee (the “Trustee”): 
 WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the
issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities
without coupons, to be authenticated by the certificate of the Trustee; 
 WHEREAS, to provide the terms and conditions upon which the
Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture; and 
 WHEREAS, all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. 
 NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable benefit of the holders of
Securities: 
 ARTICLE 1 
 DEFINITIONS 
 Section 1.1 Definitions of Terms. 
 The terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the context
otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture
that are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the
context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument. 
 “Authenticating Agent” means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant
to Section 2.10. 
 “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

 “Board of Directors” means the Board of Directors of the Company or any duly authorized committee of such Board. 
 “Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted
by the Board of Directors and to be in full force and effect on the date of such certification. 
 “Business Day” means, with
respect to any series of Securities, any day other than a day on which federal or state banking institutions in the Borough of Manhattan, the City of New York, are authorized or obligated by law, executive order or regulation to close. 

 “Certificate” means a certificate signed by the chairman of the Board of Directors, any
principal executive officer, any chief executive officer, any president, any senior vice president, any vice president, any principal financial officer or any principal accounting officer, any treasurer or any assistant treasurer, any controller or
any assistant controller, any secretary or any assistant secretary of the Company. The Certificate need not comply with the provisions of Section 13.7. 
 “Company” means Cell Therapeutics, Inc., a corporation duly organized and existing under the laws of the State of Washington, and, subject to the provisions of Article Ten, shall also include its successors
and assigns. 
 “Corporate Trust Office” means the office of the Trustee at which, at any particular time, its corporate trust
business shall be principally administered, which office at the date hereof is located at             ; Attention:
                    , except that whenever a provision herein refers to an office or agency of the Trustee in the Borough of Manhattan, the
City of New York, such office is located, at the date hereof, at             , Attn:
                    . 
 “Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law. 
 “Default” means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default. 
 “Depositary” means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global Security, The Depository Trust Company, New York, New York, another clearing
agency, or any successor registered as a clearing agency under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or other applicable statute or regulation, which, in each case, shall be designated by the Company
pursuant to either Section 2.1 or 2.11. 
 “Event of Default” means, with respect to Securities of a particular series, any
event specified in Section 6.1, continued for the period of time, if any, therein designated. 
 “Global Security” means, with
respect to any series of Securities, a Security executed by the Company and delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction, all in accordance with the Indenture, which shall be registered in the name of
the Depositary or its nominee. 
 “Governmental Obligations” means securities that are (a) direct obligations of the United
States of America for the payment of which its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is
unconditionally guaranteed as a full faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued by a bank
(as defined in Section 3(a)(2) of the Securities Act of 1933, as amended) as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian
for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount
received by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt. 
 “herein”, “hereof” and “hereunder”, and other words of similar import, refer to this Indenture as a whole and not to any
particular Article, Section or other subdivision. 
  

 2 

 “Indenture” means this instrument as originally executed or as it may from time to time be
supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof. 
 “Interest
Payment Date”, when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as
the fixed date on which an installment of interest with respect to Securities of that series is due and payable. 
 “Officers’
Certificate” means a certificate signed by a chief executive officer, a president, a senior vice president or a vice president and by the chief financial officer or the treasurer or an assistant treasurer or the controller or an assistant
controller or the secretary or an assistant secretary of the Company that is delivered to the Trustee in accordance with the terms hereof. Each such certificate shall include the statements provided for in Section 13.7, if and to the extent
required by the provisions thereof. 
 “Opinion of Counsel” means an opinion in writing subject to customary exceptions of legal
counsel, who may be an employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 13.7, if and to the extent required by
the provisions thereof. 
 “Outstanding”, when used with reference to Securities of any series, means, subject to the provisions of
Section 8.4, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the Trustee or any paying agent, or delivered
to the Trustee or any paying agent for cancellation or that have previously been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary amount shall have been
deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent); provided, however, that if such Securities
or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as in Article Three provided, or provision satisfactory to the Trustee shall have been made for giving such notice; and
(c) Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.7. 
 “Person” means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, unincorporated organization or government or any agency or political subdivision
thereof. 
 “Predecessor Security” of any particular Security means every previous Security evidencing all or a portion of the same
debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.7 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt
as the lost, destroyed or stolen Security. 
 “Responsible Officer” when used with respect to the Trustee means any officer in the
Corporate Trust Office of the Trustee, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject. 
 “Securities” means the debt Securities authenticated and delivered under this Indenture. 
 “Securityholder”, “holder of Securities”, “registered holder”, or other similar term, means the Person or Persons in whose name or names a particular Security shall be registered on the books of the Company
kept for that purpose in accordance with the terms of this Indenture. 
  

 3 

 “Subsidiary” means, with respect to any Person, (i) any corporation at least a majority of
whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii) any general partnership, joint venture or
similar entity, at least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and (iii) any
limited partnership of which such Person or any of its Subsidiaries is a general partner. 
 “Trustee” means
[                    ], and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time
there is more than one Person acting in such capacity hereunder, “Trustee” shall mean each such Person. The term “Trustee” as used with respect to a particular series of the Securities shall mean the trustee with respect to that
series. 
 “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended. 
 “Voting Stock”, as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest (however
designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the
occurrence of a contingency. 
 ARTICLE 2 
 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION 
 AND EXCHANGE OF SECURITIES 
 Section 2.1 Designation and Terms of Securities. 
 (a) The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal amount of
Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or
pursuant to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or more indentures supplemental hereto: 
 (1) the title of the Securities of the series (which shall distinguish the Securities of that series from all other Securities); 
 (2) any limit upon the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this
Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series); 
 (3) the date or dates on which the principal of the Securities of the series is payable, any original issue discount that may apply to the
Securities of that series upon their issuance, the principal amount due at maturity, and the place(s) of payment; 
 (4) the
rate or rates at which the Securities of the series shall bear interest or the manner of calculation of such rate or rates, if any; 
 (5) the date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date for
the determination of holders to whom interest is payable on any such Interest Payment Dates or the manner of determination of such record dates; 
  

 4 

 (6) the right, if any, to extend the interest payment periods and the duration of such
extension; 
 (7) the period or periods within which, the price or prices at which and the terms and conditions upon which
Securities of the series may be redeemed, in whole or in part, at the option of the Company; 
 (8) the obligation, if any, of
the Company to redeem or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments made in cash in satisfaction of future sinking fund obligations) or at the option of a holder
thereof and the period or periods within which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation; 
 (9) the form of the Securities of the series including the form of the Certificate of Authentication for such series; 
 (10) if other than denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the
Securities of the series shall be issuable; 
 (11) any and all other terms (including terms, to the extent applicable,
relating to any auction or remarketing of the Securities of that series and any security for the obligations of the Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this
Indenture, as amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations or advisable in connection with the marketing of Securities of that series; 
 (12) whether the Securities are issuable as a Global Security and, in such case, the terms and the identity of the Depositary for such
series; 
 (13) whether the Securities will be convertible into or exchangeable for shares of common stock or other securities
of the Company or any other Person and, if so, the terms and conditions upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted,
any mandatory or optional (at the Company’s option or the holders’ option) conversion or exchange features, and the applicable conversion or exchange period; 
 (14) if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable
upon declaration of acceleration of the maturity thereof pursuant to Section 6.1; 
 (15) any additional or different
Events of Default or restrictive covenants (which may include, among other restrictions, restrictions on the Company’s ability or the ability of the Company’s Subsidiaries to: incur additional indebtedness; issue additional securities;
create liens; pay dividends or make distributions in respect of their capital stock; redeem capital stock; place restrictions on such Subsidiaries placing restrictions on their ability to pay dividends, make distributions or transfer assets; make
investments or other restricted payments; sell or otherwise dispose of assets; enter into sale-leaseback transactions; engage in transactions with stockholders and affiliates; issue or sell stock of their Subsidiaries; or effect a consolidation or
merger) or financial covenants (which may include, among other financial covenants, financial covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based or asset-based ratios)
provided for with respect to the Securities of the series; 
  

 5 

 (16) if other than dollars, the coin or currency in which the Securities of the series
are denominated (including, but not limited to, foreign currency); 
 (17) the terms and conditions, if any, upon which the
Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a “United States person” for federal tax purposes; 
 (18) any restrictions on transfer, sale or assignment of the Securities of the series; and 
 (19) the subordination terms of the Securities of the series. 
 All Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or pursuant to any
such Board Resolution or in any indentures supplemental hereto. 
 If any of the terms of the series are established by action taken pursuant
to a Board Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officers’
Certificate of the Company setting forth the terms of the series. 
 Securities of any particular series may be issued at various times, with
different dates on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be
payable and with different redemption dates. 
 Section 2.2 Form of Securities and Trustee’s Certificate. 
 The Securities of any series and the Trustee’s certificate of authentication to be borne by such Securities shall be substantially of the tenor and
purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officers’ Certificate, and they may have such letters, numbers or other marks of identification or designation and such
legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made
pursuant thereto or with any rule or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage. 
 Section 2.3 Denominations: Provisions for Payment. 
 The Securities shall be issuable as
registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.1(10). The Securities of a particular series shall bear interest payable on the dates and at the rate
specified with respect to that series. The principal of and the interest on the Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency of the United States
of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose in the Borough of Manhattan, the City and State of New York. Each Security shall be dated the date of its
authentication. Interest on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months. 
 The interest
installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is
registered at the close of business on the regular 

  

 6 

 
record date for such interest installment. In the event that any Security of a particular series or portion thereof is called for redemption and the
redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in
Section 3.3. 
 Any interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment
Date for Securities of the same series (herein called “Defaulted Interest”) shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such holder; and such Defaulted Interest
shall be paid by the Company, at its election, as provided in clause (1) or clause (2) below: 
 (1) The Company may
make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close of business on a special record date for the payment of such Defaulted
Interest, which shall be fixed in the following manner: the Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the
Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the
proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted
Interest which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company
of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be mailed, first class postage prepaid, to each
Securityholder at his or her address as it appears in the Security Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date
therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date. 
 (2) The Company may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the
requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such
manner of payment shall be deemed practicable by the Trustee. 
 Unless otherwise set forth in a Board Resolution or one or more indentures
supplemental hereto establishing the terms of any series of Securities pursuant to Section 2.1 hereof, the term “regular record date” as used in this Section with respect to a series of Securities and any Interest Payment Date for
such series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.1 hereof shall occur, if such Interest Payment Date is the first
day of a month, or the last day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.1 hereof shall occur, if such Interest Payment Date is the fifteenth day of a
month, whether or not such date is a Business Day. 
 Subject to the foregoing provisions of this Section, each Security of a series
delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security. 
  

 7 

 Section 2.4 Execution and Authentications. 
 The Securities shall be signed on behalf of the Company by its chief executive officer, or one of its presidents, or one of its senior vice presidents, or
one of its vice presidents, or its chief financial officer, or its chief legal officer, or its treasurer, or one of its assistant treasurers, or its controller or one of its assistant controllers, or its secretary, or one of its assistant
secretaries, under its corporate seal attested by its secretary or one of its assistant secretaries. Signatures may be in the form of a manual or facsimile signature. 
 The Company may use the facsimile signature of any Person who shall have been a chief executive officer, president, senior vice president or vice president thereof, chief financial officer, chief legal officer,
treasurer or assistant treasurer, controller or assistant controller, secretary or assistant secretary thereof, notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed of such Person shall have
ceased to be such an officer of the Company. The seal of the Company may be in the form of a facsimile of such seal and may be impressed, affixed, imprinted or otherwise reproduced on the Securities. The Securities may contain such notations,
legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date of its authentication by the Trustee. 
 A Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated
and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company
to the Trustee for authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by a chief executive officer, president, senior vice president or any vice president, chief financial
officer, chief legal officer, treasurer or assistant treasurer, controller or assistant controller, and its secretary or any assistant secretary, and the Trustee in accordance with such written order shall authenticate and deliver such Securities.

 In authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the
Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established in conformity with the provisions of this
Indenture. 
 The Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture
will affect the Trustee’s own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee. 
 Section 2.5 Registration of Transfer and Exchange. 
 (a) Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose in the Borough of Manhattan, the City and State of New York, for other
Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this Section. In respect of any
Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the same series that the Securityholder making the exchange
shall be entitled to receive, bearing numbers not contemporaneously outstanding. 
 (b) The Company shall keep, or cause to be kept, at its
office or agency designated for such purpose in the Borough of Manhattan, the City and State of New York, or such other location designated by the 

  

 8 

 
Company, a register or registers (herein referred to as the “Security Register”) in which, subject to such reasonable regulations as it may
prescribe, the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities
and transfer of Securities as herein provided shall be appointed as authorized by Board Resolution (the “Security Registrar”). 
 Upon surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee
or transferees a new Security or Securities of the same series as the Security presented for a like aggregate principal amount. 
 All
Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form
satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder’s duly authorized attorney in writing. 
 (c) Except as provided pursuant to Section 2.1 pursuant to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or more indentures supplemental to this Indenture, no service
charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge in relation thereto, other than exchanges pursuant to Section 2.6, Section 3.3(b) and Section 9.4 not involving any transfer. 
 (d) The Company shall not be required (i) to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than
all the Outstanding Securities of the same series and ending at the close of business on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption, other
than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.5 are, with respect to any Global Security, subject to Section 2.11 hereof. 
 Section 2.6 Temporary Securities. 
 Pending the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such
temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities, all as may be determined by the
Company. Every temporary Security of any series shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series.
Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to the holders), at the
office or agency of the Company designated for the purpose in the Borough of Manhattan, the City and State of New York, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary Securities an equal
aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so exchanged, the
temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder. 
  

 9 

 Section 2.7 Mutilated, Destroyed, Lost or Stolen Securities. 
 In case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence)
shall execute, and upon the Company’s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the
mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by
them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the applicant’s Security
and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may
require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. 
 In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a
substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they
may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership thereof. 
 Every replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company whether
or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same
series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall
preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of negotiable instruments or other securities without
their surrender. 
 Section 2.8 Cancellation. 
 All Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any paying agent, be delivered to the Trustee for cancellation, or, if
surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. On request of the Company at the time of such surrender,
the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to
the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the
Trustee for cancellation. 
 Section 2.9 Benefits of Indenture. 
 Nothing in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and
the holders of the Securities (and, with respect to the 

  

 10 

 
provisions of Article Fourteen, the holders of any indebtedness of the Company to which the Securities of any series are subordinated) any legal or equitable
right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the
Securities (and, with respect to the provisions of Article Fourteen, the holders of any indebtedness of the Company to which the Securities of any series are subordinated). 
 Section 2.10 Authenticating Agent. 
 So long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized
to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and
obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each
Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or
in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating
Agent shall cease to be eligible in accordance with these provisions, it shall resign immediately. 
 Any Authenticating Agent may at any
time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to
such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor
Authenticating Agent, upon acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto. 
 Section 2.11 Global Securities. 
 (a) If the Company shall establish pursuant to Section 2.1 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in accordance with Section 2.4,
authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in the name
of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction and (iv) shall bear a legend substantially to the following effect: “Except as otherwise
provided in Section 2.11 of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary.” 
 (b) Notwithstanding the provisions of Section 2.5, the Global Security of a series may be transferred, in whole but not in part and in the manner
provided in Section 2.5, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such successor Depositary. 
 (c) If at any time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such
series or if at any time the Depositary for such series shall no 

  

 11 

 
longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is not
appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a request from the
Depositary, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.4, the Trustee will authenticate and deliver the Securities of such series in definitive
registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company may at any time
determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and,
subject to Section 2.4, the Trustee, upon receipt of an Officers’ Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form without coupons, in
authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive
registered form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall
be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the
Depositary for delivery to the Persons in whose names such Securities are so registered. 
 ARTICLE 3 
 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS 
 Section 3.1 Redemption. 
 The Company may redeem the Securities of any series issued hereunder on
and after the dates and in accordance with the terms established for such series pursuant to Section 2.1 hereof. 
 Section 3.2
Notice of Redemption. 
 (a) In case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of
the Securities of any series in accordance with any right the Company reserved for itself to do so pursuant to Section 2.1 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of
such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as they shall
appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered
holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for
the redemption of any other Securities of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this
Indenture, the Company shall furnish the Trustee with an Officers’ Certificate evidencing compliance with any such restriction. 
 Each
such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made
at the office or agency of the Company in the Borough of Manhattan, the City and State of New York, upon presentation and surrender of such Securities, that 

  

 12 

 
interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and
that the redemption is for a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to
be so redeemed. 
 In case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of
the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed portion thereof will be
issued. 
 (b) If less than all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days’
notice in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its
discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities
to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by
its chief executive officer, president or any senior vice president or vice president, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption and to give notice of redemption in the
manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent,
the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to
enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section. 
 Section 3.3 Payment Upon Redemption. 
 (a) If the giving of notice of redemption shall have been completed as above
provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest
accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued
interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at
the applicable redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest payment date, the interest installment payable on such date shall be
payable to the registered holder at the close of business on the applicable record date pursuant to Section 2.3). 
 (b) Upon
presentation of any Security of such series that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the holder thereof, at the
expense of the Company, a new Security of the same series of authorized denominations in principal amount equal to the unredeemed portion of the Security so presented. 
  

 13 

 Section 3.4 Sinking Fund. 
 The provisions of Sections 3.4, 3.5 and 3.6 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise
specified as contemplated by Section 2.1 for Securities of such series. 
 The minimum amount of any sinking fund payment provided for
by the terms of Securities of any series is herein referred to as a “mandatory sinking fund payment,” and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an
“optional sinking fund payment”. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.5. Each sinking fund payment shall be applied
to the redemption of Securities of any series as provided for by the terms of Securities of such series. 
 Section 3.5 Satisfaction
of Sinking Fund Payments with Securities. 
 The Company (i) may deliver Outstanding Securities of a series and (ii) may apply
as a credit Securities of a series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the terms of such
Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series, provided
that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and
the amount of such sinking fund payment shall be reduced accordingly. 
 Section 3.6 Redemption of Securities for Sinking Fund. 

 Not less than 45 days prior to each sinking fund payment date for any series of Securities, the Company will deliver to the Trustee an
Officers’ Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series
pursuant to Section 3.5 and the basis for such credit and will, together with such Officers’ Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date the
Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.2 and cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner
provided in Section 3.2. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section 3.3. 
 ARTICLE 4 
 COVENANTS 
 Section 4.1 Payment of Principal, Premium and Interest. 
 The Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the time and place and in the manner provided herein and established
with respect to such Securities. Payments of principal on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check drawn on and mailed to the address of the Securityholder entitled
thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series
in excess of two 

  

 14 

 
million U.S. dollars ($2,000,000) and only if such Securityholder shall have furnished wire instructions to the Trustee no later than 15 days prior to the
relevant payment date). Payments of interest on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder entitled thereto as such address
shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of two million
U.S. dollars ($2,000,000) and only if such Securityholder shall have furnished wire instructions in writing to the Security Registrar and the Trustee no later than 15 days prior to the relevant payment date). 
 Section 4.2 Maintenance of Office or Agency. 
 So long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency in the Borough of Manhattan, the City and State of New York, with respect to each such series and at such
other location or locations as may be designated as provided in this Section 4.2, where (i) Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for
registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue with respect to such office or
agency until the Company shall, by written notice signed by any officer authorized to sign an Officers’ Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them. If at any time the Company
shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company
hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company initially appoints the corporate trust office of [            ], an
affiliate of the Trustee, located in the Borough of Manhattan, the City of New York as its paying agent with respect to the Securities. 
 Section 4.3 Paying Agents. 
 (a) If the Company shall appoint one or more paying agents for all or any series of the
Securities, other than the Trustee, the Company will cause each such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section: 
 (1) that it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the
Securities of that series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto; 
 (2) that it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of
the principal of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable; 
 (3) that it will, at any time during the continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent;
and 
 (4) that it will perform all other duties of paying agent as set forth in this Indenture. 
  

 15 

 (b) If the Company shall act as its own paying agent with respect to any series of the Securities, it
will on or before each due date of the principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and
premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or any
other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of
that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and
(unless such paying agent is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act. 
 (c)
Notwithstanding anything in this Section to the contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.5, and (ii) the Company may at any time, for the purpose of
obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same
terms and conditions as those upon which such sums were held by the Company or such paying agent; and, upon such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability
with respect to such money. 
 Section 4.4 Appointment to Fill Vacancy in Office of Trustee. 
 The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10, a Trustee,
so that there shall at all times be a Trustee hereunder. 
 Section 4.5 Compliance with Consolidation Provisions. 
 The Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where the Company is
not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless the provisions of Article Ten hereof are complied with. 
 ARTICLE 5 
 SECURITYHOLDERS’ LISTS AND REPORTS 
 BY THE COMPANY AND THE TRUSTEE 
 Section 5.1 Company to Furnish Trustee Names and Addresses of Securityholders. 
 The Company will furnish or cause to be
furnished to the Trustee (a) on each regular record date (as defined in Section 2.3) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular
record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company (however, if no
regular record date is applicable with respect to a series, the Company shall furnish or cause to be furnished to the Trustee such list not later than May 16 and November 16 of each year) and (b) at such other times as the Trustee may request
in writing within 30 days after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list
need be furnished for any series for which the Trustee shall be the Security Registrar. 
  

 16 

 Section 5.2 Preservation Of Information; Communications With Securityholders. 
 (a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of
Securities contained in the most recent list furnished to it as provided in Section 5.1 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if acting in such capacity).

 (b) The Trustee may destroy any list furnished to it as provided in Section 5.1 upon receipt of a new list so furnished. 

(c) Securityholders may communicate as provided in Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their
rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust Indenture Act in accordance with the provisions of
Section 312(b) of the Trust Indenture Act. 
 Every Securityholder, by receiving and holding the same, agrees with the Company and the
Trustee that neither the Company nor the Trustee nor any agent of either of them shall be held accountable by reason of the disclosure of any such information as to the names and addresses of Securityholders in accordance with Section 312(b) of the
Trust Indenture Act, regardless of the source from which such information was derived, and that the Trustee shall not be held accountable by reason of mailing any material pursuant to a request made under Section 312(b) of the Trust Indenture Act.

 Section 5.3 Reports by the Company. 
 The Company covenants and agrees to provide a copy to the Trustee, within 15 days after the Company is required to file the same with the Securities and Exchange Commission, copies of the annual reports and of the
information, documents and other reports (or copies of such portions of any of the foregoing as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company may be required to file with the
Securities and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act. If the Company is not required to file information, documents or reports pursuant to either of said Sections, then it shall file with the
Trustee and the Securities and Exchange Commission, in accordance with rules and regulations prescribed from time to time by such commission, such of the supplementary and periodic information, documents and reports which may be required pursuant to
Section 13 of the Exchange Act, in respect of a security listed and registered on a national securities exchange as may be prescribed from time to time in such rules and regulations. 
 The Company further covenants and agrees to file with the Trustee and the Securities and Exchange Commission, in accordance with rules and regulations
prescribed from time to time by such commission, such additional information, documents and reports with respect to compliance by the Company with the conditions and covenants of this Indenture as may be required from time to time by such rules and
regulations. 
 The Company further covenants and agrees to transmit, within 30 days after the filing thereof with the Trustee, to
Securityholders, in the manner and to the extent provided in Section 313(c) of the Trust Indenture Act, such summaries of any information, documents and reports required to be filed by the Company pursuant to the immediate two preceding paragraphs
of this Section as may be required by rules and regulations prescribed from time to time by the Securities and Exchange Commission. 
 Section 5.4 Reports by the Trustee. 
 (a) On or before May 1 in each year in which any of the Securities are
Outstanding, the Trustee shall transmit by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of the preceding May 1, if and to the extent required
under Section 313(a) of the Trust Indenture Act. 
 (b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust
Indenture Act. 
 (c) A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the
Company, with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The Company agrees to notify the Trustee when any Securities become listed on any securities exchange.

 ARTICLE 6 
 REMEDIES
OF THE TRUSTEE AND SECURITYHOLDERS 
 ON EVENT OF DEFAULT 
 Section 6.1 Events of Default. 
 (a) Whenever used herein with respect to Securities of a particular series, “Event of Default” means any one or more of the following events that has occurred and is continuing: 
 (1) the Company defaults in the payment of any installment of interest upon any of the Securities of that series, as and when the same
shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental hereto shall not
constitute a default in the payment of interest for this purpose; 
  

 17 

 (2) the Company defaults in the payment of the principal of (or premium, if any, on) any
of the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that
series; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any; 
 (3) the Company fails to observe or perform any other of its covenants or agreements with respect to that series contained in this
Indenture or otherwise established with respect to that series of Securities pursuant to Section 2.1 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for the benefit of one or more series of
Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a “Notice of Default” hereunder, shall have been given to
the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time Outstanding; 
 (4) the Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the
entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the benefit of its creditors; or

 (5) a court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is for relief against the
Company in an involuntary case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 90 days.

 (b) In each and every such case (other than an Event of Default specified in clause (4) or clause (5) above), unless the
principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that series then Outstanding hereunder, by notice in
writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable immediately, and upon any
such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all the Securities of that
series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities. 
 (c) At any time after the principal of (and premium, if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the
payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company and the
Trustee, may rescind and annul such declaration and its consequences if: (i) the Company has paid or deposited with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the
principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under
applicable law, upon overdue installments of interest, at the rate per annum expressed in the 

  

 18 

 
Securities of that series to the date of such payment or deposit) and the amount payable to the Trustee under Section 7.6, and (ii) any and all
Events of Default under the Indenture with respect to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not have become due by their terms, shall
have been remedied or waived as provided in Section 6.6. 
 No such rescission and annulment shall extend to or shall affect any
subsequent default or impair any right consequent thereon. 
 (d) In case the Trustee shall have proceeded to enforce any right with respect
to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in
every such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall
continue as though no such proceedings had been taken. 
 Section 6.2 Collection of Indebtedness and Suits for Enforcement by
Trustee. 
 (a) The Company covenants that (i) in case it shall default in the payment of any installment of interest on any of the
Securities of a series, and such default shall have continued for a period of 90 Business Days, or (ii) in case it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall
have become due and payable, whether upon maturity of the Securities of a series or upon redemption or upon declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that series as and when the
same shall have become due and payable, then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all
such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon
overdue installments of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the
Trustee under Section 7.6. 
 (b) If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name
and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to judgment or final
decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the property of
the Company or other obligor upon the Securities of that series, wherever situated. 
 (c) In case of any receivership, insolvency,
liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein
that may be permitted by the court and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the
holders of Securities of such series allowed for the entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after
such date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same 

  

 19 

 
after the deduction of the amount payable to the Trustee under Section 7.6; and any receiver, assignee or trustee in bankruptcy or reorganization is
hereby authorized by each of the holders of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to the Trustee any
amount due it under Section 7.6. 
 (d) All rights of action and of asserting claims under this Indenture, or under any of the terms
established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding
instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section 7.6, be for the ratable benefit of the
holders of the Securities of such series. 
 In case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect
and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise, whether for
the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.

 Nothing contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any
Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any
such proceeding. 
 Section 6.3 Application of Moneys Collected. 
 Any moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the following order, at
the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment, if only
partially paid, and upon surrender thereof if fully paid: 
 FIRST: To the payment of reasonable costs and expenses of collection and of all
amounts payable to the Trustee under Section 7.6; 
 SECOND: To the payment of all indebtedness of the Company to which such series of
Securities is subordinated to the extent required by Article Fourteen; 
 THIRD: To the payment of the amounts then due and unpaid upon
Securities of such series for principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable
on such Securities for principal (and premium, if any) and interest, respectively; and 
 FOURTH: To the payment of the remainder, if any, to
the Company or any other Person lawfully entitled thereto. 
  

 20 

 Section 6.4 Limitation on Suits. 
 No holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or
proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice
of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided; (ii) the holders of not less than 25% in aggregate principal amount of the
Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii) such holder or holders shall have offered to the Trustee such
reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby; (iv) the Trustee for 90 days after its receipt of such notice, request and offer of indemnity, shall have failed to institute
any such action, suit or proceeding and (v) during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request. 
 Notwithstanding anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive
payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption, on the redemption date), or to institute suit for
the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting a Security hereunder it is expressly understood, intended and covenanted
by the taker and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any manner whatsoever by virtue or by availing of any
provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or to enforce any right under this Indenture,
except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder and the Trustee shall
be entitled to such relief as can be given either at law or in equity. 
 Section 6.5 Rights and Remedies Cumulative; Delay or
Omission Not Waiver. 
 (a) Except as otherwise provided in Section 2.7, all powers and remedies given by this Article to the Trustee
or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise, to enforce the
performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities. 
 (b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such right or power, or shall be
construed to be a waiver of any such default or an acquiescence therein; and, subject to the provisions of Section 6.4, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised from time to
time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders. 
 Section 6.6 Control by Securityholders.

 The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in
accordance with Section 8.4, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or 

  

 21 

 
power conferred on the Trustee with respect to such series; provided, however, that such direction shall not be in conflict with any rule of law or with this
Indenture. Subject to the provisions of Section 7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee, determine that the proceeding
so directed, subject to the Trustee’s duties under the Trust Indenture Act, would involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority in
aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with Section 8.4, may on behalf of the holders of all of the Securities of such series waive any past default in the
performance of any of the covenants contained herein or established pursuant to Section 2.1 with respect to such series and its consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the
Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any
premium has been deposited with the Trustee (in accordance with Section 6.1(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company, the Trustee and the holders of
the Securities of such series shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon. 
 Section 6.7 Undertaking to Pay Costs. 
 All parties to this Indenture agree, and each holder of any Securities by such holder’s acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or
remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its
discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this
Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit
instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this
Indenture. 
 ARTICLE 7 
 CONCERNING THE TRUSTEE 
 Section 7.1 Certain Duties and Responsibilities of Trustee. 
 (a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default
with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this Indenture, and no implied covenants
shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee shall exercise with respect to Securities of that series such
of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. 
 (b) No provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to
act, or its own willful misconduct, except that: 
  

 22 

 (i) prior to the occurrence of an Event of Default with respect to the Securities of a
series and after the curing or waiving of all such Events of Default with respect to that series that may have occurred: 
 (A) the duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such
series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and 
 (B) in the absence of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively
rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but in the case of any such certificates
or opinions that by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirement of this Indenture; 
 (ii) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the
Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; 
 (iii) the Trustee
shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding
relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series; and

 (iv) None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or
otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds or liability is not reasonably
assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it. 
 Section 7.2 Certain Rights of Trustee. 
 Except as otherwise provided in Section 7.1: 
 (a) The Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion,
report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties; 
 (b) Any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed
in the name of the Company by any authorized officer of the Company (unless other evidence in respect thereof is specifically prescribed herein); 
  

 23 

 (c) The Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel
shall be full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon; 
 (d) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the Securityholders pursuant to the provisions of this
Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the
Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by
this Indenture, and to use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs; 
 (e) The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the
discretion or rights or powers conferred upon it by this Indenture; 
 (f) The Trustee shall not be bound to make any investigation into the
facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less
than a majority in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.4); provided, however, that if the payment within a reasonable time to the Trustee of the costs,
expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require
reasonable indemnity against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand;
and 
 (g) The Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through
agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder. 
 Section 7.3 Trustee Not Responsible for Recitals or Issuance or Securities. 
 (a) The recitals contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the
correctness of the same. 
 (b) The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the
Securities. 
 (c) The Trustee shall not be accountable for the use or application by the Company of any of the Securities or of the proceeds
of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.1, or for the use or application of any moneys received by any
paying agent other than the Trustee. 
  

 24 

 Section 7.4 May Hold Securities. 
 The Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the
same rights it would have if it were not Trustee, paying agent or Security Registrar. 
 Section 7.5 Moneys Held in Trust.

 Subject to the provisions of Section 11.5, all moneys received by the Trustee shall, until used or applied as herein provided, be
held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it hereunder except such as
it may agree with the Company to pay thereon. 
 Section 7.6 Compensation and Reimbursement. 
 (a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited
by any provision of law in regard to the compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services rendered by it in the execution of the trusts hereby created and in the
exercise and performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and
advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in its employ), except any
such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents,
directors and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection with the acceptance or administration of this
trust, including the reasonable costs and expenses of defending itself against any claim of liability in the premises. 
 (b) The obligations
of the Company under this Section to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall constitute indebtedness of the Company to which the Securities are subordinated.
Such additional indebtedness shall be secured by a lien prior to that of the Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular Securities.

 Section 7.7 Reliance on Officers’ Certificate. 
 Except as otherwise provided in Section 7.1, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably
necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of
negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officers’ Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part of the
Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof. 
  

 25 

 Section 7.8 Section 7.8 Disqualification; Conflicting Interests. 
 If the Trustee has or shall acquire any “conflicting interest” within the meaning of Section 310(b) of the Trust Indenture Act, the Trustee
and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act. 
 Section 7.9
Corporate Trustee Required; Eligibility. 
 There shall at all times be a Trustee with respect to the Securities issued hereunder which
shall at all times be a corporation organized and doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the
Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers, having (or, in the case of a subsidiary of a bank holding company, its bank holding company parent shall have) a combined capital and surplus of at
least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial, or District of Columbia authority. 
 If such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section,
the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company may not, nor may any Person directly or
indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in
the manner and with the effect specified in Section 7.10. 
 Section 7.10 Resignation and Removal; Appointment of Successor. 
 (a) The Trustee or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving written notice
thereof to the Company and by transmitting notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the Security Register. Upon receiving such notice of resignation,
the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning
Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of
competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of
himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. 
 (b) In case at any time any one of the following shall occur: 
 (i) the Trustee shall fail to comply with the provisions of Section 7.8 after written request therefor by the Company or by any
Securityholder who has been a bona fide holder of a Security or Securities for at least six months; or 
 (ii) the Trustee
shall cease to be eligible in accordance with the provisions of Section 7.9 and shall fail to resign after written request therefor by the Company or by any such Securityholder; or 
  

 26 

 (iii) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or
insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the
purpose of rehabilitation, conservation or liquidation; 
 then, in any such case, the Company may remove the Trustee with respect to all
Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any
Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the
appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. 
 (c) The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding may at any time remove the Trustee
with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company. 
 (d) Any resignation or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective upon acceptance
of appointment by the successor trustee as provided in Section 7.11. 
 (e) Any successor trustee appointed pursuant to this Section may
be appointed with respect to the Securities of one or more series or all of such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series. 
 Section 7.11 Acceptance of Appointment By Successor. 
 (a) In case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and to the retiring
Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the
rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor
trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder. 
 (b) In case of the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not all) series, the Company, the
retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall accept such appointment and which (i) shall contain
such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which
the appointment of such successor trustee relates, (ii) shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of
that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or
facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall 

  

 27 

 
constitute such Trustees co-trustees of the same trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any
trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible for any act or failure to act on the part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture
the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor trustee relates
have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture, and each such successor trustee, without any further act, deed or conveyance, shall
become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates; but, on request of the Company or any successor
trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee hereunder with respect to the
Securities of that or those series to which the appointment of such successor trustee relates. 
 (c) Upon request of any such successor
trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case
may be. 
 (d) No successor trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be
qualified and eligible under this Article. 
 (e) Upon acceptance of appointment by a successor trustee as provided in this Section, the
Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such notice
within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company. 
 Section 7.12 Merger, Conversion, Consolidation or Succession to Business. 
 Any corporation into
which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially
all of the corporate trust business of the Trustee (including the administration of the trust created by this Indenture), shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of
Section 7.8 and eligible under the provisions of Section 7.9, without the execution or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities
shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the
same effect as if such successor Trustee had itself authenticated such Securities. 
 Section 7.13 Preferential Collection of Claims
Against the Company. 
 The Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship
described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein. 
  

 28 

 Section 7.14 Notice of Default 
 If any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer of the Trustee,
the Trustee shall mail to each Securityholder in the manner and to the extent provided in Section 313(c) of the Trust Indenture Act notice of the Default or Event of Default within 45 days after it occurs, unless such Default or Event of
Default has been cured; provided, however, that, except in the case of a default in the payment of the principal of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as
the board of directors, the executive committee or a trust committee of directors and/or Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interest of the Securityholders. 
 ARTICLE 8 
 CONCERNING THE
SECURITYHOLDERS 
 Section 8.1 Evidence of Action by Securityholders. 
 Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a
particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or
specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in person or by agent or proxy appointed in writing.

 If the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver
or other action, the Company may, at its option, as evidenced by an Officers’ Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand, authorization, direction,
notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be given before or after the
record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of Outstanding Securities of
that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed as of the record date;
provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six months after
the record date. 
 Section 8.2 Proof of Execution by Securityholders. 
 Subject to the provisions of Section 7.1, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or
his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner: 
 (a)
The fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee. 
 (b) The ownership of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof. 
  

 29 

 The Trustee may require such additional proof of any matter referred to in this Section as it shall deem
necessary. 
 Section 8.3 Who May be Deemed Owners. 
 Prior to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security shall be
registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar) for the
purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section 2.3) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any Security
Registrar shall be affected by any notice to the contrary. 
 Section 8.4 Certain Securities Owned by Company Disregarded.

 In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in
any direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under
common control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee
shall be protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded
as Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly
controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the
Trustee. 
 Section 8.5 Actions Binding on Future Securityholders. 
 At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.1, of the taking of any action by the holders of the
majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to be included in the
Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.2, revoke such action so far as concerns such Security. Except as aforesaid any
such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in
place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified
in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series. 
  

 30 

 ARTICLE 9 
 SUPPLEMENTAL INDENTURES 
 Section 9.1 Supplemental Indentures Without the Consent of
Securityholders. 
 In addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from
time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following
purposes: 
 (a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series; 
 (b) to comply with Article Ten; 
 (c) to
provide for uncertificated Securities in addition to or in place of certificated Securities; 
 (d) to add to the covenants, restrictions,
conditions or provisions relating to the Company for the benefit of the holders of all or any series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities,
stating that such covenants, restrictions, conditions or provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants,
restrictions, conditions or provisions an Event of Default, or to surrender any right or power herein conferred upon the Company; 
 (e) to
add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth; 
 (f) to make any change that does not adversely affect the rights of any Securityholder in any material respect; 
 (g) to provide for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.1, to
establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of Securities; 
 (h) to evidence and provide for the acceptance of appointment hereunder by a successor trustee; or 
 (i) to comply with any requirements of the Securities and Exchange Commission or any successor in connection with the qualification of this Indenture
under the Trust Indenture Act. 
 The Trustee is hereby authorized to join with the Company in the execution of any such supplemental
indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee’s own rights, duties or
immunities under this Indenture or otherwise. 
 Any supplemental indenture authorized by the provisions of this Section may be executed by
the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.2. 
  

 31 

 Section 9.2 Supplemental Indentures With Consent of Securityholders. 
 With the consent (evidenced as provided in Section 8.1) of the holders of not less than a majority in aggregate principal amount of the Securities of
each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental
hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture
or of modifying in any manner not covered by Section 9.1 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the holders of each
Security then Outstanding and affected thereby, (a) extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or reduce any premium
payable upon the redemption thereof or (b) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture. 
 It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any
proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof. 
 Section 9.3
Effect of Supplemental Indentures. 
 Upon the execution of any supplemental indenture pursuant to the provisions of this Article or of
Section 10.1, this Indenture shall, with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of
the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of
any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes. 
 Section 9.4 Securities Affected by Supplemental Indentures. 
 Securities of any series affected by a supplemental
indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article or of Section 10.1, may bear a notation in form approved by the Company, provided such form meets the
requirements of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of
the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding.

 Section 9.5 Execution of Supplemental Indentures. 
 Upon the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing
with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the
Trustee’s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of
Section 7.1, may receive an Officers’ Certificate or an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or permitted by, 

  

 32 

 
and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof;
provided, however, that such Officers’ Certificate or Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.1 hereof.

 Promptly after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the
Trustee shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby as their names and addresses appear upon the
Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture. 
 ARTICLE 10 
 SUCCESSOR ENTITY 
 Section 10.1 Company May Consolidate, Etc. 
 Except as provided pursuant to Section 2.1 pursuant to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or more indentures supplemental to this Indenture, nothing
contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the Company) or successive consolidations or mergers in which the Company or its successor or
successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its successor or successors as an entirety, or substantially as an entirety, to any other corporation
(whether or not affiliated with the Company or its successor or successors) authorized to acquire and operate the same; provided, however, the Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if the
Company is not the survivor of such transaction), sale, conveyance, transfer or other disposition, (a) the due and punctual payment of the principal of (premium, if any) and interest on all of the Securities of all series in accordance with the
terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture with respect to each series or established with respect to such series pursuant to
Section 2.1 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture Act, as then in effect) reasonably satisfactory in form to the Trustee
executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such property and (b) in the event that the Securities of any series
then Outstanding are convertible into or exchangeable for shares of common stock or other securities of the Company, such entity shall, by such supplemental indenture, make provision so that the Securityholders of Securities of that series shall
thereafter be entitled to receive upon conversion or exchange of such Securities the number of securities or property to which a holder of the number of shares of common stock or other securities of the Company deliverable upon conversion or
exchange of those Securities would have been entitled had such conversion or exchange occurred immediately prior to such consolidation, merger, sale, conveyance, transfer or other disposition. 
 Section 10.2 Successor Entity Substituted. 
 (a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered to the Trustee and
satisfactory in form to the Trustee, of the obligations set forth under Section 10.1 on all of the Securities of all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had
been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities. 
  

 33 

 (b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such
changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate. 
 (c)
Nothing contained in this Article shall require any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of such transaction, or the acquisition by the Company, by purchase
or otherwise, of all or any part of the property of any other Person (whether or not affiliated with the Company). 
 Section 10.3
Evidence of Consolidation, Etc. to Trustee. 
 The Trustee, subject to the provisions of Section 7.1, may receive an Officers’
Certificate or an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the provisions of this Article. 
 ARTICLE 11 
 SATISFACTION AND
DISCHARGE 
 Section 11.1 Satisfaction and Discharge of Indenture. 
 If at any time: (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated and not
delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section 2.7 and Securities for whose payment money or Governmental
Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.5); or (b) all such Securities of a particular
series not theretofore delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within one year under arrangements satisfactory to
the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of
a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee for
cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable
hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.3, 2.5, 2.7, 4.1, 4.2, 4.3 and 7.10, that shall survive until
the date of maturity or redemption date, as the case may be, and Sections 7.6 and 11.5, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost and expense of the Company shall execute proper
instruments acknowledging satisfaction of and discharging this Indenture with respect to such series. 
 Section 11.2 Discharge of
Obligations. 
 If at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that
have not become due and payable as described in Section 11.1 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon
redemption all such Securities of that 

  

 34 

 
series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of
maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental
Obligations, as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.3, 2.5, 2.7, 4,01, 4.2, 4,03,
7.6, 7.10 and 11.5 hereof that shall survive until such Securities shall mature and be paid. 
 Thereafter, Sections 7.6 and 11.5 shall
survive. 
 Section 11.3 Deposited Moneys to be Held in Trust. 
 All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.1 or 11.2 shall be held in trust and shall be available for
payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations
have been deposited with the Trustee. 
 Section 11.4 Payment of Moneys Held by Paying Agents. 
 In connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the
provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations. 
 Section 11.5 Repayment to Company. 
 Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of or premium, if any, or interest on the Securities of a particular series that are not
applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on such Securities shall have respectively become due and payable, or such other
shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Company’s request or (if then held by the Company) shall be discharged from such
trust; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment shall thereafter, as
a general creditor, look only to the Company for the payment thereof. 
 ARTICLE 12 
 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 
 Section 12.1 No Recourse. 
 No recourse under or upon any obligation, covenant or agreement of
this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or
successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being
expressly understood that this Indenture and the obligations 

  

 35 

 
issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the
incorporators, stockholders, officers or directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations,
covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any
and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in
this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities. 
 ARTICLE 13 
 MISCELLANEOUS PROVISIONS

 Section 13.1 Effect on Successors and Assigns. 
 All the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and assigns,
whether so expressed or not. 
 Section 13.2 Actions by Successor. 
 Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company
shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company. 
 Section 13.3 Surrender of Company Powers. 
 The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the powers reserved to the Company, and thereupon such power so surrendered shall
terminate both as to the Company and as to any successor corporation. 
 Section 13.4 Notices. 
 Except as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted to be given,
made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on the Company may be given or served by being deposited in first class mail, postage prepaid, addressed (until another address is
filed in writing by the Company with the Trustee), as follows: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119, Attention: Louis A. Bianco (telecopy no.: (206) 284-6206). Any notice, election, request or
demand by the Company or any Securityholder or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office
of the Trustee. 
 Section 13.5 Governing Law. 
 This Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State, except to the
extent that the Trust Indenture Act is applicable. 
  

 36 

 Section 13.6 Treatment of Securities as Debt. 
 It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture
shall be interpreted to further this intention. 
 Section 13.7 Compliance Certificates and Opinions. 
 (a) Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall
furnish to the Trustee an Officers’ Certificate stating that all conditions precedent provided for in this Indenture relating to the proposed action have been complied with and an Opinion of Counsel stating that in the opinion of such counsel
all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular
application or demand, no additional certificate or opinion need be furnished. 
 (b) Each certificate or opinion provided for in this
Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a statement that the Person making such certificate or opinion has read such covenant or condition; (ii) a
brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; (iii) a statement that, in the opinion of such Person, he has made such
examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to whether or not, in the opinion of such
Person, such condition or covenant has been complied with. 
 Section 13.8 Payments on Business Days. 
 Except as provided pursuant to Section 2.1 pursuant to a Board Resolution, and set forth in an Officers’ Certificate, or established in one or
more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and
premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal date. 
 Section 13.9 Conflict with Trust Indenture Act. 
 If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act, such imposed duties shall control.

 Section 13.10 Counterparts. 
 This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. 
 Section 13.11 Separability. 
 In
case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not
affect any other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein. 
  

 37 

 Section 13.12 Compliance Certificates. 
 The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were outstanding, an
Officers’ Certificate stating whether or not the signers know of any Default or Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial
officer or principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company’s performance under this Indenture and that the Company has complied with all conditions and covenants
under this Indenture. For purposes of this Section 13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If any of the officers of the Company signing such
certificate has knowledge of such a Default or Event of Default, the certificate shall describe any such Default or Event of Default and its status. 
 ARTICLE 14 
 SUBORDINATION OF SECURITIES 
 Section 14.1 Subordination Terms. 
 The payment by the Company of the principal of, premium, if
any, and interest on any series of Securities issued hereunder shall be subordinated to the extent set forth in an indenture supplemental hereto relating to such Securities. 
  

 38 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of
the day and year first above written. 
  

			
	CELL THERAPEUTICS, INC.
		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	
	
	[                                       
                                         
],
	as Trustee
		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

  

 39 

 CROSS-REFERENCE TABLE* 
  

					
	 TIA SECTION
	  	 INDENTURE SECTION

	Section	  	310(a)(1)	  	 7.9

		  	(a)(2)	  	 7.9

		  	(a)(3)	  	N/A**
		  	(a)(4)	  	N/A**
		  	(a)(5)	  	 7.9

		  	(b)	  	 7.8, 7.10, 7.11

		  	(c)	  	N/A**
			
	Section	  	311(a)	  	 7.13

		  	(b)	  	 7.13

		  	(c)	  	N/A**
			
	Section	  	312(a)	  	5.1, 5.2
		  	(b)	  	5.2
		  	(c)	  	5.2
			
	Section	  	313(a)	  	5.4
		  	(b)(1)	  	N/A**
		  	(b)(2)	  	5.4
		  	(c)	  	5.4
		  	(d)	  	5.4
			
	Section	  	314(a)	  	5.3, 13.12
		  	(b)	  	N/A**
		  	(c)(1)	  	13.7
		  	(c)(2)	  	13.7
		  	(c)(3)	  	N/A**
		  	(d)	  	N/A**
		  	(e)	  	13.7
		  	(f)	  	N/A**
			
	Section	  	315(a)	  	7.1(b)
		  	(b)	  	 7.14

		  	(c)	  	7.1(a)
		  	(d)	  	7.1(b)
		  	(e)	  	 6.7

			
	Section	  	316(a)(last sentence)	  	1.1, 8.4
		  	(a)(1)(A)	  	 6.6

		  	(a)(1)(B)	  	 6.6

		  	(a)(2)	  	N/A
		  	(b)	  	6.4

					
	 TIA SECTION
	  	 INDENTURE SECTION

	Section	  	317(a)(1)	  	6.2(b)
		  	(a)(2)	  	6.2(c)
		  	(b)	  	4.3
			
	Section	  	318(a)	  	13.9

  

	*	This Cross-Reference Table shall not, for any purpose, be deemed a part of this Indenture. 

  

	**	N/A means Not ApplicableDevelopment and Supply Agreement

			
		  	 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT
 HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
 COMMISSION.

 Exhibit 10.1 
 DEVELOPMENT AND SUPPLY AGREEMENT 
 THIS DEVELOPMENT AND
SUPPLY AGREEMENT (this “Agreement”) is made as of this 26th day of March, 2009 (the “Effective Date”) by and between MediciNova, Inc., having a principal place of
business at 4350 La Jolla Village Drive, Suite 950, San Diego, California 92122 (“MediciNova”) and Hospira Worldwide, Inc., having a principal place of business at 275 North Field Drive, Lake Forest, Illinois 60045
(“Hospira”). 
 WITNESSETH: 
 WHEREAS, MediciNova has rights to develop and commercialize
the compound MN-221, a highly-selective ß2-adrenergic receptor agonist, and wishes to develop and market MN-221 in Hospira’s ADD-Vantage® Drug Delivery System (as further defined
herein); 
 WHEREAS, MediciNova and Hospira desire that Hospira assist MediciNova in the development and
commercialization of Products; and 
 WHEREAS, after MediciNova has received an approved New Drug
Application from the U.S. Food and Drug Administration (the “FDA”) or a corresponding new drug approval in the Territory, the parties desire that Hospira manufacture and sell to MediciNova its full requirements of Products in
accordance with the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the premises and the mutual promises and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties, MediciNova and Hospira agree as
follows. 
 Article 1     DEFINITIONS 
 The following words and phrases when used herein with capital letters shall have the meanings set forth or referenced below: 
 1.1 “API” shall mean the active pharmaceutical ingredient referred to as MN-221 in bulk form that MediciNova shall
deliver to Hospira for incorporation into the Products (as hereinafter defined) and meeting the applicable Active Pharmaceutical Ingredient Specifications (as hereinafter defined). 
 1.2 “API Specifications” shall mean the detailed description and parameters of the API set forth on Exhibit
1.2, as may be amended from time to time by MediciNova. 
 1.3
“ADD-Vantage® Drug Delivery System” shall mean the ADD-Vantage® Vial and the ADD-Vantage® diluent container to be used in combination to deliver an intravenous dose of a drug contained in the ADD-Vantage® Vial. 

 

 -1- 

 1.4 “ADD-Vantage® Vial(s)” shall mean the drug vial designed and promoted by Hospira under Hospira trademarks (including the “ADD-Vantage” ® trademark) for the aseptic transfer of a drug from a vial into a compatible partial-fill, intravenous fluid container, more fully described in the Product Specifications. 
 1.5 “Affiliate” shall mean any corporation or non-corporate business entity which controls, is controlled by, or
is under common control with a party to this Agreement at any time during the term of this Agreement. A corporation or non-corporate business entity shall be regarded as in control of another corporation or non-corporate business entity if it owns,
or directly or indirectly controls, in excess of fifty percent (50%) of the voting stock or membership interests of the other entity or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and
policies of such corporation or non-corporate business entity, as applicable. 
 1.6 “Applicable
Law” shall mean all applicable laws, rules, regulations, guidelines, and standards including, without limitation, ICH guidelines, cGMPs and those relating to the environment, food or drugs and occupational health and safety, including
all enforced or promulgated by the FDA, [***] and any relevant Regulatory Authority in the Territory. 
 1.7
“cGMP” shall mean the current good manufacturing practices required by the FDA and set forth in the United States Federal Food, Drug and Cosmetic Act or FDA regulations (including, without limitation, 21 C.F.R. Part 210 and
Part 211), policies or guidelines in effect at any time during the term of this Agreement for the manufacture and testing of pharmaceutical products as applied to the Products, and all corresponding requirements of the [***] and of each other
applicable Regulatory Authority, including, without limitation, relevant ICH manufacturing guidelines. 
 1.8
“Commercialization Year” shall mean a period of twelve (12) consecutive months which, for the first Commercialization Year of this Agreement, shall commence on the first day of the month after the month of
MediciNova’s first bona fide commercial sale (“Product Launch”) of Products to a non-Affiliate customer after the Products have received an approved NDA from the FDA or [***] and each Commercialization Year thereafter
shall consist of twelve (12) consecutive months following the end of the preceding Commercialization Year. 
 1.9
“Confidential Information” shall mean the proprietary and confidential information of a party disclosed under this Agreement, part of a prior disclosure, or developed hereunder, except any portion thereof which: 

(a) is known to the recipient at the time of the disclosure, as evidenced by its written records or other competent evidence;

  

 -2- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (b) is disclosed to the recipient by a third person lawfully in possession of such
information and not under an obligation of nondisclosure; 
 (c) is published or generally known to the public, either before
or after the date of disclosure through no act or omission on the part of the recipient; 
 (d) is developed by or for the
recipient independently of Confidential Information disclosed hereunder as evidenced by the recipient’s written records or other competent evidence; or 
 (e) is required by law to be disclosed by the recipient, to defend or prosecute litigation or to comply with governmental regulations,
provided that the recipient gives the other party hereto prompt prior written notice of such legal requirement, such that such other party shall have the opportunity to apply for confidential treatment of such Confidential Information, and
reasonably cooperates therewith. The confidential information of MediciNova will be deemed to include all information concerning the MNOV Project IP and the terms and existence of this Agreement, as well as all information relating to the API.

 1.10 “Hospira IP” shall mean (i) Hospira’s rights and interests in and to issued patents
and pending patent applications without limitation to any country, including, without limitation, all provisional applications, substitutions, continuations, continuations-in-part, divisionals, and renewals, all letters patent granted thereon, and
all re-issues, re-examinations and extensions thereof, and supplemental protection certificates relating thereto whether owned solely or jointly by Hospira or under which Hospira has or later obtains rights that permit Hospira to grant sublicenses,
which relate to [***]; (ii) [***]; and (iii) any Improvements to the foregoing. 
 1.11
“ICH” shall mean International Conference on Harmonisation. 
 1.12
“Improvements” shall mean any and all new developments by a party in connection with this Agreement, including, but not limited to, with respect to Hospira IP, [***] and, with respect to MediciNova IP, [***]. 
 1.13 “MediciNova IP” shall mean: (i) MediciNova’s rights and interests in and to issued patents and
pending patent applications without limitation to any country, including, without limitation, all provisional applications, substitutions, continuations, continuations-in-part, divisionals, and renewals, all letters patent granted thereon, and all
re-issues, re-examinations and extensions thereof, and supplemental protection certificates relating thereto whether owned solely or jointly by MediciNova, which relate to [***]; (ii) [***]; and (iii) any Improvements to the foregoing.

  

 -3- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 1.14 New ADD-Vantage® Drug Delivery System” shall mean a changed Hospira drug delivery system that: [***]. 
 1.15 “NDA” shall mean New Drug Application filed with the FDA guidelines for a Product. 
 1.16 [***]. 
 1.17
“Product” or “Products” shall mean the dosage form(s) of the API (as defined herein) processed, filled, finished, labeled, packaged and inspected by Hospira in ADD-Vantage® Vials (as defined herein) and supplied to MediciNova as either an individual vial (“Vial Product”) or in kit form with a 250mL 5% dextrose solution in an ADD-Vantage® diluent container (each, a “Kit”). For purposes of clarification, Hospira shall manufacture the Products exclusively for MediciNova. 
 1.18 “Product Placebo” shall mean a form of the Product intended for human use and manufactured fully in
accordance with the Product Specifications, but without the inclusion of the API. For purposes of this Agreement, the terms “Product” and “Products” shall include Product Placebo unless the context
specifically requires otherwise. 
 1.19 “Product Specifications” shall mean those product, labeling
and performance specifications for the Products filed with the FDA, [***] or other appropriate Regulatory Authorities, including Product formulae, labeling, and materials required for the manufacture of the Products that are to be purchased and
supplied under this Agreement, as such are set forth on Exhibit 1.19, which specifications may be amended from time to time by the written agreement of the parties, which agreement will not be unreasonably withheld. 
 1.20 “Product Supply Commitment” shall have the meaning provided in Section 6.1. 
 1.21 “Purchase Order” shall mean written orders from MediciNova to Hospira, which shall specify: (a) the
quantity of Products ordered; (b) delivery dates; and (c) delivery destinations. 
 1.22 “Regulatory
Authority” shall mean, with respect to the Territory, any federal, state or local or international regulatory agency, department, bureau or other governmental entity including without limitation the FDA and [***], which is responsible
for issuing approvals, licenses, registrations or authorizations necessary for the manufacture, use, storage, import, transport or sale of the Products in the Territory. 
 1.23 “Specially Regulated Waste” shall mean any hazardous waste, toxic waste, medical waste, nuclear waste, mixed
waste, or other waste materials or by-products, including waste water, which is subject to or requires special handling, treatment, storage, or disposal under any federal, state or local laws or regulations intended to address such types of waste
materials that arise from the manufacture of the Products and is solely attributable to the API. 
  

 -4- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 1.24 “Technology” shall mean and include any and all unpatented
proprietary ideas, inventions, patents, patent applications, discoveries, Confidential Information, trade secrets, biologic materials, data, results, formulae, designs, specifications, methods, processes, formulations, techniques, ideas, know-how,
technical information (including, without limitation, structural and functional information), process information, pre-clinical information, clinical information, and any and all proprietary biological, chemical, pharmacological, toxicological,
pre-clinical, clinical, assay, control, manufacturing data and materials. 
 1.25 “Territory” shall
mean [***]. 
 1.26 “Third Party” shall mean a party other than Hospira or MediciNova and their
respective Affiliates. 
 1.27 “Waste” shall mean all waste, rejects, improper goods, garbage, refuse,
remainder, residue, waste water or other discarded material, including solid, liquid, semisolid, or contained gaseous material that arises from the manufacture of the Products, including but not limited to, rejected, excess or unsuitable materials,
API and Products, all to the extent solely attributable to the API. The term Waste shall not include any Specially Regulated Waste. 
 Article 2     PRODUCT DEVELOPMENT PROJECT 
 2.1 General. In accordance with a Letter of Intent dated [***] (the “LOI”) which has expired as of the date hereof, the parties have undertaken a Product development project (the
“Project”) consisting of certain of the development activities set forth in Exhibit 2.1. The objective of the Project shall be for Hospira to assist in the development of the Products and to assist MediciNova in
obtaining an approved NDA (and/or foreign equivalents) covering the Products. The parties acknowledge and agree that all such development work referred to in Exhibit 2.1 and all payments relating thereto, shall be subject to the terms and
conditions of this Agreement. Upon completion of the Project, Hospira shall manufacture and deliver the Products to MediciNova for ultimate commercial sale by MediciNova as a human pharmaceutical product, as herein provided. Hospira shall otherwise
manufacture and deliver clinical Products as ordered by MediciNova. 
 2.2 Commercially Reasonable Efforts. Each
party shall use its commercially reasonable efforts to successfully complete the Project [***]. However, the parties agree and understand that neither party hereto [***], provided such agreement and understanding will not in any way lessen either
party’s obligations to fulfill its duties hereunder. 
  

 -5- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Article 3     PAYMENT FOR
HOSPIRA’S DEVELOPMENT EFFORTS 
 3.1 Development
Fee. To reimburse Hospira for the development work related to the Project, MediciNova shall pay to Hospira development fees set forth in Exhibit 2.1 (the “Development Fee”). The Development Fee shall be paid to
Hospira in accordance with the payment schedule set forth in Exhibit 3.1. 
 3.2 Changes in Project
Scope. If changes occur in the Project or the Product Specifications or if technical difficulties require that Hospira perform either additional work or repeat work, the parties shall consult and agree to execute written amendments to the
scope of work. Each amendment shall detail the requested changes to the applicable tasks, responsibilities, duties, budgets, timelines or other matters relating to scope of work for this Agreement. Hospira shall provide MediciNova with cost
estimates for such work. If MediciNova approves in writing such amendment and estimated costs, Hospira shall perform such work and, if such changes or technical difficulties are not attributable to Hospira’s acts or omissions, MediciNova shall
pay the agreed-upon additional costs for such work within thirty (30) days of completion of such work. Hospira’s estimate of the costs for such additional work or repeat work shall be based on the full time equivalent rates for Hospira
personnel (“FTE Rates”) as set forth in Exhibit 3.2, plus out-of-pocket costs for reasonable travel and sustenance, materials and supplies, or such other costs agreed by the parties prior to the commencement of the
additional work or repeat work. 
 3.3 Development Supplies. After MediciNova selects its final Product
formulations, concentration, and fill volume and the parties mutually agree to the final Product Specifications, such agreement of Hospira not to be unreasonably withheld, Hospira will provide to MediciNova all development supplies of Products
ordered by MediciNova at the prices set forth on Exhibit 5.8. MediciNova shall issue a purchase order for any such development supplies at least [***] before the required delivery date. 
 Article 4     MEDICINOVA’S REGULATORY SUBMISSIONS

 4.1 Regulatory Approvals. MediciNova will advise Hospira of all document requirements in support of its
NDA, [***] and similar applications required by relevant Regulatory Authorities, including amendments, license applications, supplements and maintenance of the same. Hospira shall comply with all reasonable requests of MediciNova in providing
appropriate documentation and will assist MediciNova in preparation of submissions to Regulatory Authorities designated by MediciNova in support of MediciNova’s regulatory submissions in the Territory. All regulatory submission preparation
currently to be performed by Hospira for MediciNova is specified in Exhibit 2.1. 
  

 -6- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 4.2 Review. Hospira shall have the right to review and consult on those
specific portions of MediciNova’s proposed regulatory submissions directly relating to Hospira’s packaging or manufacturing procedures before the submissions are filed with appropriate Regulatory Authorities. Hospira shall complete its
review of the submissions within sixty (60) days for submissions in English, or within ninety (90) days for submissions not in English, after receipt of a proposed regulatory submission. Hospira shall consult with and advise MediciNova in
responding to questions from Regulatory Authorities regarding MediciNova’s submission(s) for the Products, as well as provide all reasonable assistance requested by MediciNova in connection with the writing, filing, prosecution and maintenance
of its regulatory filings. MediciNova shall be the sole owner of any regulatory submission filed pursuant to this Agreement. MediciNova shall provide to Hospira for its files a final copy of those specific portions of MediciNova’s proposed
regulatory submissions directly relating to Hospira’s development work, manufacturing procedures or other activities under this Agreement of any such regulatory submission(s). 
 4.3 Expansion of the Territory/International Filings. In the event that MediciNova decides to pursue the expansion of the
Territory beyond [***], Hospira shall fully cooperate with all relevant support that it can reasonably provide for such expansion including, without limitation, regulatory support for filings, packaging and product development, labeling, and
inspections. MediciNova agrees that all such activities will be paid for by MediciNova at rates to be agreed by the Parties, which rates shall reasonably reflect pricing charged to its other customers for similar services. [***]. MediciNova shall
own and be fully responsible for all regulatory filings for countries for any such expanded Territory, provided that if Hospira believes that it or its customers might realize some strategic or commercial benefit or advantage from such filings, the
Parties may agree in writing that Hospira will defray a portion of the costs for the expansion of the Territory. 
 4.4
Access to Drug Master Files. Hospira hereby grants MediciNova reference rights to all Drug Master Files (“DMFs”) necessary to support MediciNova’s applications for marketing authorizations of the Products.
To effect this, Hospira shall execute all documentation helpful or required for reference (“Letters of Authorization”) which shall be delivered to the appropriate Regulatory Authorities permitting such Regulatory Authorities
to reference Hospira’s DMFs in their review of MediciNova’s Product marketing applications. Hospira shall send copies of such Authorization Letters to MediciNova. Hospira shall update its DMFs annually and shall inform MediciNova prior to
any modifications thereto in order to permit MediciNova to amend or supplement any affected regulatory applications and filings for the Products. 
 4.5 User Fees. MediciNova shall pay any FDA (or foreign equivalent, if applicable) user fees which may become payable for the Products. 
  

 -7- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Article 5     MANUFACTURE AND SUPPLY
OF PRODUCTS 
 5.1 Purchase and Sale of Products. Pursuant to the terms and
conditions of this Agreement and for the duration of this Agreement, Hospira shall manufacture, sell and deliver to MediciNova its total worldwide requirements for the Products and MediciNova shall purchase and take delivery of its total worldwide
requirements of Products exclusively from Hospira. 
 5.2
Obligation to Manufacture. Hospira guarantees to MediciNova that for [***] from the Effective Date (the “Guarantee Period”) it will supply to MediciNova Product using the ADD-Vantage® Drug Delivery System (whether as Vial Product or Kits) and it will not cease production of the Product utilizing the ADD-Vantage® Drug Delivery System
during the Guarantee Period. [***]. 
 5.3 New
ADD-Vantage® Drug Delivery System. 
 (a) Subject to Hospira’s obligation to manufacture Product for the Guarantee
Period, which shall not be altered in any way by this Section 5.3, if during the term of this Agreement, Hospira develops and commercializes a New ADD-Vantage® Drug Delivery
System and desires to discontinue manufacture of the Products as part of an overall determination to discontinue manufacturing of the ADD-Vantage® Drug Delivery System, Hospira agrees to
give MediciNova no less than [***] written notice prior to such determination. In connection therewith, Hospira grants to MediciNova [***]. 
 (b) If (i) [***]; (ii) [***]; or (iii) [***], then MediciNova shall
have, at its option, the right to terminate this Agreement upon [***] written notice to Hospira or to have Hospira continue to manufacture the Products for MediciNova for so long as Hospira continues to manufacture the ADD-Vantage® Drug Delivery System. 
 5.4 Government Approvals.
Notwithstanding any other provision of this Agreement, Hospira shall have no obligation to manufacture, sell or deliver Products to MediciNova and MediciNova shall have no obligation to purchase and take delivery of the Products for commercial sale
in a specific country until MediciNova has obtained all necessary Regulatory Authorities’ approvals required to sell the Products in such country. However, Hospira agrees to manufacture and supply those quantities of the Products requested in
Purchase Orders by MediciNova that are helpful or reasonably necessary for development of each Product and to build MediciNova’s inventory in anticipation of commercial launch of the Products and [***]. 
  

 -8- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 5.5 API. 
 (a) Supply. Hospira shall manufacture the Products for MediciNova from API that MediciNova shall supply to Hospira at no
cost, unless Hospira is responsible for the supply of replacement API (whether in bulk or Product form) in accordance with Section 5.5(e) below. MediciNova shall supply API to Hospira in quantities sufficient to satisfy Hospira’s
gross manufacturing requirements of the Products on a schedule agreed by the parties. At no time will MediciNova be required to provide Hospira more than [***]. Hospira shall use the API received from MediciNova only for the development work
contemplated by this Agreement and the manufacture of the Products for MediciNova. MediciNova shall deliver the API [***] to Hospira’s manufacturing facility, pursuant to no-cost purchase orders that Hospira issues to MediciNova. Within thirty
(30) days of Hospira’s receipt of any API supplied by MediciNova hereunder, Hospira shall: (i) perform an identification test on the API and confirm the shipment quantity; and (ii) notify MediciNova of any inaccuracies with
respect to quantity or of any claim that any portion of the shipment fails the identification test. In the event Hospira notifies MediciNova of any deficiency in the quantity of API received, [***]. In the event Hospira notifies MediciNova that the
API shipment does not conform to the API Specifications, MediciNova shall have the right to confirm such findings at Hospira’s manufacturing location or a sample will be sent to MediciNova for testing if requested by MediciNova. If MediciNova
determines that such shipment of API conformed to the API Specifications, the parties shall submit samples of such shipment to a mutually acceptable independent laboratory for testing. If such independent laboratory determines that the shipment
conformed to the API Specifications, Hospira shall bear all expenses of shipping and testing such shipment samples. If MediciNova or such independent laboratory confirms that such shipment did not meet the API Specifications, MediciNova shall
replace, at no cost to Hospira, the portion of the API shipment which does not conform to the API Specifications and bear all expenses of shipping and testing the shipment samples. 
 (b) API Title. MediciNova shall retain title to the API at all times. Subject to the limitation in
Section 5.5(e), risk of loss or damage to the API shall remain with Hospira while the API is in its control; provided, however, that all quantities of API have been properly shipped to Hospira and that MediciNova has fully disclosed to
Hospira all conditions reasonably necessary for the safe handling, storage, use and disposal of the API. 
 (c)
Specified Uses. Hospira agrees that the API shall: (i) only be used as specified in writing by MediciNova and not for any other purpose; (ii) only be made accessible to those employees of Hospira who need access in order to
carry out the manufacturing of the Products; (iii) be used in compliance at all times with all Applicable Laws; (iv) be carefully secured and not be transferred to any Affiliate or third party without the explicit prior written consent of
MediciNova; (v) not be reverse engineered; and (vi) not be subjected to testing procedures, except as specified in this Agreement or otherwise agreed in writing by the parties. 
  

 -9- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (d) Records. Hospira shall maintain detailed records of the location and
use of the API while it is in its possession and shall provide MediciNova a reasonable accounting of the same upon request. 
 (e) Replacement. In the event of any loss or damage of any API delivered hereunder or the failure of the Products to meet Product Specifications, MediciNova shall supply to Hospira at no cost replacement API according to the
terms set forth in Section 5.5(a), [***]. 
 5.6 Dedicated Equipment Costs. If non-standard,
specialized equipment (including, but not limited to specialized equipment to manufacture Products) is required to manufacture the Products for MediciNova, Hospira shall pay the cost of such equipment subject to MediciNova’s prior approval of
such costs. Hospira shall advise MediciNova of specialized equipment that is unique to and required for the Project and the manufacture of the Products and the estimated costs associated with the purchase, installation and validation of such
equipment. After MediciNova approves such costs, Hospira shall install and validate the equipment and bill MediciNova for the associated costs. MediciNova shall make payment to Hospira no later than thirty (30) days after MediciNova receives an
invoice from Hospira. Title to the equipment shall be in MediciNova’s name. All such equipment paid for by MediciNova shall be owned solely by MediciNova; provided, however, that such equipment shall remain at Hospira’s [***] facility (or
such other Hospira facility mutually agreed to by the parties) and shall be available for Hospira’s use solely in connection with the manufacture of Products for MediciNova. Hospira shall not use such equipment for any other purpose, shall not
transfer such equipment to any third party or other location, shall not purport to convey or grant to any third party an interest in such equipment and shall not take any action inconsistent with MediciNova’s ownership of such equipment. During
the term of this Agreement, Hospira shall be responsible for maintaining, servicing and insuring such equipment to the same extent and in the same manner as Hospira maintains services and insures its own equipment. Hospira shall maintain appropriate
records regarding the use, maintenance and service of such equipment. If Hospira wishes to use the specialized equipment for manufacture of products other than the Products for MediciNova, Hospira shall promptly notify MediciNova, and Hospira and
MediciNova shall meet and discuss the technical and practical ramifications of such use and appropriate compensation to MediciNova, provided MediciNova may withhold its consent for such use in its sole discretion. 
 5.7 Product Labeling. Hospira shall label the Products in accordance with label copy that MediciNova provides. Such copy may
be modified from time to time by MediciNova. MediciNova shall reimburse Hospira for Hospira’s actual costs of making any label copy changes and for the reasonable agreed cost of any labeling that Hospira is unable to use due to such label copy
changes. 
  

 -10- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 5.8 Off-Site Waste. If necessary, Hospira shall hire, direct and pay all
reasonable agreed costs for a waste contractor to remove all Waste from Hospira’s manufacturing facility for the Products consistent with the Products’ Material Safety Data Sheets (“MSDS”). The reasonable, agreed
costs associated with the removal of Specially Regulated Waste shall be borne by MediciNova. Hospira shall only dispose of Specially Regulated Waste at sites and through waste management vendors that have been approved in writing by MediciNova,
whose approval shall not be withheld unreasonably. Hospira shall document the destruction of any Specially Regulated Waste in writing and provide copies of such written documentation to an authorized representative of MediciNova. MediciNova
maintains the right, but not the obligation, to witness the actual disposal of Specially Regulated Waste. MediciNova shall, upon request by Hospira, provide the MSDS for the API and the MSDS for the Products to Hospira. All other costs for waste
disposal shall be Hospira’s. 
 5.9 Delivery. Hospira shall deliver the Products to MediciNova, [***]. Risk
of loss over the Products shall pass to MediciNova at the time when they are made available to MediciNova’s designated carrier at Hospira’s facility loading dock. Shipment shall be via a carrier designated by MediciNova. For shipments to
destinations outside the United States, MediciNova shall be the exporter of record. [***]. 
 5.10 Price and
Payment. 
 (a) Price. Hospira shall invoice MediciNova for the Products delivered by Hospira at the
prices set forth on Exhibit 5.8. Prices are firm through [***]. Beginning [***] and on each succeeding [***] during the term hereof, prices may be increased by Hospira. Price increases shall be effective for deliveries beginning [***] of each
calendar year. Such increases shall not exceed the lesser of (i) [***]; and (ii) [***]. 
 (b)
Payment. Hospira shall invoice MediciNova upon shipment of the Products following release by Hospira’s Quality Assurance department in accordance with the Quality Agreement. MediciNova shall make payment net thirty (30) days
from the date of receipt of Hospira’s invoice. 
 (c) Taxes. Any federal, state, county or municipal sales
or use tax, excise, customs charges, duties or similar charge, or any other tax assessment (other than that assessed against income), license, fee or other charge lawfully assessed or charged on the purchase by MediciNova of the Products sold
pursuant to this Agreement shall be paid by MediciNova. 
 (d) Process Rework. Process rework created as a
result of MediciNova’s changes shall be billed separately at a reasonable fee mutually agreed upon in writing. Reprocess work required as a result of Hospira’s acts or omissions shall be without charge, upon the request of MediciNova.

  

 -11- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (e) Sub-lots. Should MediciNova desire Hospira to split a manufacturing lot
of the Products into several sub-lots during packaging, there will be a split fee of [***]. 
 (f) Storage Fee.
A storage fee shall be due and payable to Hospira if MediciNova stores Product at Hospira’s plant for more than two (2) weeks after Product’s final release; provided, that such release is made in accordance with MediciNova’s
requested delivery dates for the Products. The fee shall be [***]. 
 (g) Acceptance of Products/Replacement of
Nonconforming Shipment. MediciNova shall have a period of [***] from the date of its receipt of a shipment of the Products to inspect and reject such shipment for nonconformance with the Product Specifications. If MediciNova rejects such
shipment, it shall promptly so notify Hospira and provide to Hospira samples of such shipment for testing. If Hospira tests such shipment and determines that it did conform to the Product Specifications, the parties shall submit samples of such
shipment to a mutually acceptable independent laboratory for testing. If such independent laboratory determines that the shipment conformed to the Product Specifications, MediciNova shall bear all expenses of shipping and testing such shipment
samples. If Hospira or such independent laboratory confirms that such shipment did not meet the Product Specifications, Hospira shall replace, at no cost to MediciNova, that portion of a Product shipment which does not conform to the Product
Specifications, and shall bear all expenses of shipping and testing the shipment samples. Any nonconforming portion of any shipment shall be destroyed as directed by Hospira, at Hospira’s expense. Any Products that MediciNova does not reject
pursuant to this Section 5.10(g) shall be deemed accepted with respect to meeting Product Specifications, and all claims with respect to the Products not conforming with the Product Specifications shall be deemed waived by MediciNova,
except as to latent defects which are not reasonably discoverable. MediciNova shall not be required to pay Hospira for any Product which has been finally rejected pursuant to this Section 5.10(g). Hospira shall replace all finally
rejected Product at no additional cost to MediciNova as soon as reasonably possible after receipt of test results confirming nonconformance with the Product Specifications. 
 Article 6     ORDERS AND FORECASTS 
 6.1 [***] Product Supply Forecast. For the sake of clarity, the provisions of this Article 6 apply only to
commercial Products and not to Products to be used in clinical trials. For capacity planning purposes, [***] prior to Product Launch, MediciNova shall provide Hospira with a written forecast of MediciNova’s total annual requirements of the
Products for [***]. Thereafter, by [***] of each calendar year, MediciNova shall update such rolling [***] forecast of its requirements of the Products for the period commencing on [***]. Hospira shall provide a written confirmation of its receipt
of the forecast and will allocate its annual capacity to manufacture the Products for MediciNova. Such forecast shall constitute Hospira’s Product supply commitment (“Product Supply Commitment”) for each of the calendar
years covered by the forecast. 
  

 -12- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 6.2 First Year Estimate. MediciNova shall, within [***] after submitting
its NDA application for regulatory approval of Product, provide Hospira with a written estimate of MediciNova’s [***] requirements of the Products to be supplied by Hospira for the first Commercialization Year. Hospira acknowledges that such
quantities are estimates only and are nonbinding. 
 6.3 First Order. Hospira and MediciNova shall cooperate
fully in estimating and scheduling production for the first commercial order of Products to be placed by MediciNova with Hospira in anticipation of regulatory approval of the Products. 
 6.4 First Firm Order. MediciNova shall place its first firm order approximately [***] in advance of the anticipated Product
regulatory approval date or desired Product availability date. At the same time, MediciNova shall provide to Hospira MediciNova’s estimate of its monthly requirements of the Products to be supplied by Hospira for the next succeeding [***].

 6.5 Rolling Forecast. Thereafter, MediciNova shall provide quarterly to Hospira a rolling [***] forecast of
requirements of the Products to be supplied by Hospira. The first [***] of such forecast shall constitute a binding commitment upon MediciNova to purchase such quantities and MediciNova shall issue, concurrently with such forecast, Purchase Orders
for the [***] of that forecast which were not included in the firm order period of the previous forecast (“Firm Purchase Orders”). The remaining [***] of such forecast shall consist of MediciNova’s reasonable best
estimate projection of its Product requirements for that period. 
 6.6 Purchase Orders. 
 (a) MediciNova shall submit each Purchase Order to Hospira at least [***] prior to the requested delivery date of the Products. Cumulative
Purchase Orders with respect to any Firm Purchase Order period shall be not less than the amount of the Firm Purchase Order. 
 (b) Each Purchase Order or any acknowledgment thereof, whether printed, stamped, typed, or written shall be governed by the terms of this Agreement and none of the provisions of such purchase order or acknowledgment shall be applicable
except those specifying Product and quantity ordered, delivery dates, special shipping instructions and invoice information. 
 (c) At all times during the term of this Agreement, Hospira shall use its commercially reasonable efforts to meet the delivery dates set forth in each Purchase Order. In the event that Hospira believes it may miss a delivery date in a
purchase order submitted by MediciNova, Hospira shall promptly give MediciNova written notice of the same specifying in detail the reasons for the late delivery. In such case, Hospira may deliver Products up to fifteen (15) days following the
specified delivery date. 
  

 -13- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 6.7 Purchase Order Acceptance. As soon as practicable but no later than
thirty (30) days after receipt of MediciNova’s Purchase Orders issued in accordance with Section 6.6, Hospira shall confirm to MediciNova its acceptance of the purchase order, delivery date and quantity of Product ordered by
MediciNova. Notwithstanding anything to the contrary herein, Hospira may reject a Purchase Order only if it: (a) calls for the delivery of Product for which sufficient quantities of API have not been delivered or will not be delivered by
MediciNova or its designee in accordance with Section 5.5(a) or such shorter time as otherwise reasonably required for manufacture; or (b) sets forth a delivery schedule that is inconsistent with Section 6.6(a). 

6.8 Minimum Purchase Requirement. Beginning at the first Commercialization Year, MediciNova covenants to purchase from
Hospira not less than [***] (the “Minimum Purchase Requirement”). [***]. 
 6.9 Obligation to
Supply Additional Product. Hospira shall be obligated to supply MediciNova up to [***] more Product than previously forecasted or ordered in Purchase Orders. Hospira shall not be obligated to supply additional quantities over and above the
[***] excess; provided, however, that Hospira shall, until MediciNova’s orders in the aggregate reach the applicable annual Product Supply Commitment, use reasonable commercial efforts to produce and deliver to MediciNova said additional
quantities above the [***] within [***] of issuance of the Purchase Orders for such additional quantities. 
 6.10 Firm
Commercial Order Changes or Cancellations. 
 (a) If MediciNova requests changes to Purchase Orders of Products within
the Purchase Order timeframe, Hospira shall attempt to accommodate the changes within reasonable manufacturing capabilities and efficiencies. If Hospira can accommodate such change, Hospira shall advise MediciNova of the costs associated with making
any such change and MediciNova shall be deemed to have accepted the obligation to pay Hospira for such costs if MediciNova indicates in writing to Hospira that Hospira should proceed to make the change. If Hospira cannot accommodate such change,
MediciNova shall be bound to the original Purchase Order. 
 (b) If MediciNova cancels a Firm Purchase Order, [***].

 (c) If MediciNova does not supply sufficient API to manufacture such order, other than as a result of API loss due to the
negligence, willful misconduct or breach of Hospira, [***]. Notwithstanding anything to the contrary contained herein, all Products paid for by MediciNova shall count toward the Minimum Purchase Requirement of the Products, including, without
limitation, any payments made in the event of a cancellation. 
  

 -14- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Article 7     QUALITY 
 7.1 Quality Control. Hospira shall apply its quality control procedures and in-plant quality control checks on the
manufacture of the Products for MediciNova in the same manner as Hospira applies such procedures and checks to products bearing like qualities to the drug manufactured for sale by Hospira. In addition, Hospira will test and release the Products in
accordance with the test methods described in Exhibit 7.1 to ensure that the Products conform to the Product Specifications. The parties may change the test methods from time to time by mutual agreement. Hospira shall provide for each lot of
Product purchased pursuant to this Agreement a certificate of manufacturing compliance which will certify that the lot of Product was manufactured in accordance with the Product Specifications and cGMPs, as the same may be amended from time to time.

 7.2 Quality Agreement. The parties shall enter into a quality agreement substantially in the form of the
agreement attached hereto as Exhibit 7.2 within one-hundred and twenty (120) days following the Effective Date. 
 7.3 Audit Rights. 
 (a) MediciNova shall have the right, upon sixty (60) days prior written
notice to Hospira, to conduct, at its expense and during normal business hours, a quality assurance audit and inspection of Hospira’s records and production facilities relating to the manufacturing, assembly and/or packaging of the Products.
Except as provided in Section 7.3(b), such audits shall, assuming the full cooperation of Hospira, (a) be limited to not more than two (2) auditors appointed or representing MediciNova, (b) last for not more than two
(2) days per facility and (c) may be conducted not more than one (1) time per calendar year. If MediciNova wishes to perform not-for-cause audits more often than once per year or over a period in excess of two (2) days,
MediciNova shall pay Hospira [***]. Any auditors that are not employees of MediciNova shall be required to enter into confidentiality agreements with Hospira and MediciNova containing terms of confidentiality at least as stringent as those set forth
in Article 11 hereof. 
 (b) MediciNova shall have the right to conduct additional audits in response to
incidents/deviations associated with the manufacture/testing of the Products, given that a reasonable advanced notice is provided to Hospira. Visits by MediciNova to Hospira production facilities may involve the transfer of Confidential Information,
and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11 and shall not be disclosed to Third
Parties, including, but not limited to, the FDA, unless required by law and only then upon prior written notice to Hospira, to the extent practicable. 

  

 -15- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 
Hospira also agrees to allow the FDA or other relevant Regulatory Authorities to conduct any audit which the FDA or other relevant Regulatory Authorities
require, and Hospira agrees to reasonably cooperate with the FDA and other Regulatory Authorities in connection with any such audit. In the event that any audit or inspection reveals that Hospira failed to meet cGMPs or the Product Specifications,
Hospira will be responsible, at Hospira’s expense, for: (a) conducting an investigation to define the probable causes for the failure; (b) providing an acceptable cGMP investigation report to MediciNova for review; and
(c) achieving compliance with cGMPs and the Product Specifications. 
 7.4 Notification of Inspection. In
the event the FDA or other Regulatory Authority notifies Hospira that it intends to visit or inspect its facilities relating to the manufacture of Product or storage of API, the following shall apply: (a) Hospira shall immediately provide
notice of such visit or inspection to MediciNova; (b) Hospira shall permit a representative of MediciNova to be present at the facility during such visit or inspection; (c) Hospira shall permit such representative of MediciNova to be
present at, and participate in, each daily wrap up session for such inspection and the post-inspection wrap up session for such inspection; (d) Hospira promptly shall provide MediciNova with copies of all written materials, including, without
limitation, copies of any Notice of Inspection (FDA Form 482), other notice of inspection, notice of violation, other similar notice or Inspectional Observations (FDA Form 483) received by Hospira relating to such inspection; and (e) Hospira
shall provide MediciNova with advance copies of all proposed responses to any such inspections, notices or actions, shall permit MediciNova reasonable opportunity to review and comment on each such response, shall reasonably consider
MediciNova’s reasonable comments thereon and shall provide MediciNova with copies of each such response as submitted. In addition, Hospira shall advise MediciNova immediately if an authorized agent of the FDA or other Regulatory Authority
visits any Hospira facilities relating to the manufacture of Product or storage of API without prior notice. Hospira shall furnish to MediciNova the report by such agency of any such visit within thirty (30) days of Hospira’s receipt of
such report. 
 7.5 Customer Representative in Plant. 
 (a) In addition to the audit rights stated in Section 7.3, MediciNova, at its own expense, shall have the right to appoint a
technician to be assigned to each Hospira facility where any Product or component thereof is manufactured, assembled or packaged (“Customer Representative in Plant”) at such times and for such periods as, in the opinion of
MediciNova, is necessary to monitor compliance with this Agreement, or to coordinate and advise on the proper manufacture of the Products by Hospira. While at the Hospira facility, the Person in the Plant shall have access solely to such areas of
the Hospira facility in accordance with Hospira’s Customer Representative in Plant guidelines that are: (i) reasonably related 

  

 -16- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 
to the manufacture of the Product; (ii) food- service areas; (iii) designated office space as may be allocated to the Customer Representative in
Plant by Hospira; (iv) public areas within the facility; or (v) as otherwise authorized by Hospira. The Customer Representative in Plant shall comply with all applicable Hospira policies and procedures (including without limitation all
Hospira security policies and procedures and the Customer Representative in Plant guidelines) as provided to MediciNova in writing. MediciNova hereby represents that any and all of its employees visiting the Hospira facility shall be bound by terms
of confidentiality no less restrictive than those set forth in Article 11. In accordance with Hospira’s Customer Representative in Plant guidelines, any MediciNova Customer Representative in Plant must be escorted at all times when in
manufacturing areas of the Hospira facility. 
 (b) With respect to any Customer Representative in Plant, Hospira shall
provide at no cost to MediciNova: (i) an on-site office; (ii) a conference room (if necessary for meetings), access to which shall be available per the scheduling process used by Hospira employees; (iii) parking facilities and toilet
facilities; as well as (iv) reasonable access to and use of telephone, facsimile and photocopying services necessary to perform any activities relating to the manufacturing, storage and/or quality testing of the Product at each Hospira
facility. 
 7.6 Notification of Complaints. MediciNova shall notify Hospira promptly of any Product complaints
involving Hospira’s manufacture or packaging in sufficient time to allow Hospira to evaluate the complaints and assist MediciNova in responding to such complaints. 
 7.7 Product Recalls. In the event: (a) any Regulatory Authority or other national government authority issues a
request, directive or order that the Products be recalled; (b) a court of competent jurisdiction orders such a recall or withdrawal; or (c) MediciNova or Hospira reasonably determines that the Products should be recalled or withdrawn, the
parties shall take all appropriate corrective actions, and shall cooperate in any governmental investigations surrounding the recall. In the event that such recall results from the breach of Hospira’s express warranties under this Agreement or
its negligence or willful misconduct, Hospira shall be responsible for promptly replacing the quantity of Products that were recalled at no cost to MediciNova or reimbursing MediciNova for the total cost of the Products that were recalled. In
addition, Hospira shall be responsible for [***]. To the extent that the recall does not result from the breach of Hospira’s express warranties under this Agreement, or its negligence or willful misconduct, MediciNova shall be responsible for
the expenses of the recall and Hospira will have no obligation to replace recalled Products. 
  

 -17- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Article 8     WARRANTIES; COVENANTS
AND INDEMNIFICATION 
 8.1 MediciNova’s Warranties. 
 (a) MediciNova represents and warrants to Hospira that all API delivered to Hospira pursuant to this Agreement shall, at the time of
delivery, not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act, as amended, (the “Act”) or within the meaning of any applicable state or municipal law in which the definitions of
adulteration and misbranding are substantially the same as those contained in the Act, as the Act and such laws are constituted and effective at the time of delivery and will not be an article which may not under the provisions of Sections 404 and
505 of the Act be introduced into interstate commerce. 
 (b) MediciNova further warrants to Hospira that API supplied to
Hospira hereunder shall meet the API Specifications set forth on Exhibit 1.2. 
 (c) MediciNova further warrants that
all specifications, including API Specifications and Product Specifications, that MediciNova provides to Hospira shall conform to the NDA or foreign equivalents that MediciNova files with the appropriate Regulatory Authorities. 
 (d) MediciNova further represents and warrants to Hospira that MediciNova’s performance of its obligations under this Agreement will
not result in a material violation or breach of any agreement, contract, commitment or obligation to which MediciNova is a party or by which it is bound and will not conflict with or constitute a default under its corporate charter or bylaws.

 (e) MediciNova further represents and warrants that it will not sell the Products into any jurisdiction for ultimate
commercial use by end users in that jurisdiction unless and until it receives the necessary Regulatory Authority approvals for such sale. 
 8.2 Hospira’s Warranties and Covenants. 
 (a) Hospira represents and
warrants to MediciNova that the Products Hospira delivers to MediciNova pursuant to this Agreement shall: (i) at the time of delivery, not be adulterated or misbranded within the meaning of the Act or within the meaning of any applicable state
or municipal law in which the definitions of adulteration and misbranding are substantially the same as those contained in the Act, as the Act and such laws are constituted and effective at the time of delivery; (ii) will be an article which
may under the provisions of Sections 404 and 505 of the Act be introduced into interstate commerce; and (iii) for Vial Products, have at the date of delivery an expiry date of not less than [***], assuming [***] of total shelf life, and [***]
assuming [***] of total shelf life; and (iv) for Kits, have at the date of delivery an expiry date of not less than [***], assuming [***] of total shelf life for the ADD-Vantage diluent container. 
  

 -18- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Hospira further represents and warrants to MediciNova that the Products Hospira
delivers to MediciNova pursuant to this Agreement shall, at the time of delivery, be free from defects in material and workmanship and shall have been manufactured: (i) in accordance and conformity with the Product Specifications; and
(ii) in compliance with all Applicable Law. 
 (c) Hospira further represents and warrants to MediciNova that
Hospira’s performance of its obligations under this Agreement will not result in a material violation or breach of any agreement, contract, commitment or obligation to which Hospira or its Affiliates is a party or by which it is bound and will
not conflict with or constitute a default under its Certificate of Incorporation or corporate bylaws. Hospira shall obtain and maintain all licenses and permits useful or necessary in order to meet its obligations hereunder. 
 (d) The foregoing warranties shall not extend to any nonconformity or defect to the extent that such nonconformity or defect relates to or
is caused by API as supplied by MediciNova to Hospira. 
 (e) Hospira
further represents and warrants that it shall perform all obligations hereunder in compliance with all Applicable Laws, Hospira’s standard operating procedures, and consistently high standards of workmanship and professionalism. With respect to
Product delivered hereunder, Hospira has, and shall have, all the rights necessary to manufacture and sell as part of the Product the ADD-Vantage® Drug Delivery System components.

 (f) EXCEPT AS SET FORTH IN THIS AGREEMENT, HOSPIRA MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
PRODUCTS. ALL OTHER WARRANTIES, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY HOSPIRA, PROVIDED THE FOREGOING IN NO WAY LESSENS THE FORCE, COVERAGE OR EFFECT OF
ANY WARRANTY SET FORTH IN THIS AGREEMENT. 
 8.3 Mutual Warranties – Debarment. Each party hereby certifies
it does not and shall not employ, contract with or retain any person directly or indirectly to perform any of its obligations relating to this Agreement if such person is debarred under 21 U.S.C. 335a (a) or (b) or other equivalent laws,
rules, regulations or standards of any other jurisdiction. Upon written request of a party, the other party shall, within ten (10) business days, provide written confirmation that it has complied with the foregoing obligation. Each party agrees
to promptly disclose in writing to the other party if any employee or agent is debarred, or if any action or investigation is pending or, to the best of its knowledge, threatened, relating to the debarment of it or any person performing services
related to this Agreement. 
  

 -19- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 8.4 Indemnification by
Hospira. Hospira shall indemnify, defend and hold harmless MediciNova, its Affiliates, officers, directors and employees from and against all claims, causes of action, suits, costs and expenses (including reasonable attorney’s fees),
losses or liabilities of any kind related to this Agreement and asserted by third parties to the extent such claims arise out of or are attributable to: (a) Hospira’s breach of this Agreement; (b) the ADD-Vantage® Drug Delivery System; (c) any violation of any proprietary right of any Third Party relating to Hospira’s manufacturing processes or the ADD-Vantage® Drug Delivery System; or (d) any negligent or wrongful act or omission on the part of Hospira, its employees, agents or representatives or any latent defect in the Products to the extent attributable to Hospira.

 8.5 Indemnification by MediciNova. MediciNova shall indemnify, defend and hold harmless Hospira, its
Affiliates, officers, directors and employees from and against all claims, causes of action, suits, costs and expenses (including reasonable attorney’s fees), losses or liabilities of any kind related to this Agreement and asserted by third
parties to the extent such claims arise out of or are attributable to: (a) MediciNova’s breach of this Agreement; (b) any violation of any proprietary right of any Third Party relating to the API Specifications or the composition of
API; (c) the use of or lack of safety or efficacy of the API as supplied by MediciNova; or (d) any negligent or wrongful act or omission on the part of MediciNova, its employees, agents or representatives. 
 8.6 Conditions of Indemnification. If either party seeks indemnification from the other hereunder, it shall promptly give
notice to the other party of any such claim or suit threatened, made or filed against it which forms the basis for such claim of indemnification and shall cooperate fully with the other party in the investigation and defense of all such claims or
suits. The indemnifying party shall have the option to assume the other party’s defense in any such claim or suit with counsel reasonably satisfactory to the other party. No settlement or compromise shall be binding on a party hereto without
its prior written consent, such consent not to be unreasonably withheld. 
 8.7 No Consequential Damages.
NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES RESULTING FROM ANY BREACH OF THIS AGREEMENT EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, PROVIDED
THE FOREGOING SHALL NOT APPLY TO LOSSES RELATED TO THIRD PARTY CLAIMS; BREACHES OR ARTICLES 9 OR 11; OR WILLFUL MISCONDUCT, GROSS NEGLIGENCE OR FRAUD. 
  

 -20- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Article 9     INTELLECTUAL PROPERTY
RIGHTS 
 9.1 Grant License. Hospira hereby grants to MediciNova an exclusive license under
the Hospira IP and the Hospira marks to test, have tested, develop, have developed, market, have marketed, promote, have promoted, sell, have sold, use, and have used the Products supplied by Hospira to MediciNova in accordance with this Agreement.
MediciNova shall not use any Hospira IP and the Hospira marks, except as authorized by Hospira hereunder. 
 9.2 Project
Inventions. Except as provided in Section 9.1, Hospira has granted no license, express or implied, to MediciNova to use the Hospira IP or other patents, know-how, trade secrets, proprietary information or other intellectual
property rights that are proprietary to Hospira. With respect to any inventions, Improvements, or Technology developed or conceived by Hospira pursuant to or in connection with this Agreement (“Project IP”),
(i) MediciNova is hereby the sole and exclusive owner of [***] (“MNOV Project IP”) and (ii) Hospira shall be the owner of [***] (“Hospira Project IP”). Ownership of all other Project
IP shall be determined by U.S. law (“Other Project IP”). Hospira hereby grants to MediciNova a world-wide, royalty-free nonexclusive license to (i) the Hospira Project IP for use with API and (ii) the Other Project
IP for any purpose. Hospira shall assign, and does hereby assign, to MediciNova all of its right, title and interest in and to such MNOV Project IP. Hospira agrees to execute such documents and take such actions as MediciNova may from time to time
reasonably request to effect the foregoing assignment. However, MediciNova shall grant to Hospira, and does hereby grant to Hospira an exclusive, perpetual, fully paid, worldwide royalty-free license, with the right to sublicense to Affiliates and
Third Parties under the MNOV Project IP and the MediciNova IP for the purpose of the manufacture of the Products exclusively for MediciNova, provided all such Affiliates and Third Parties shall be approved by MediciNova in writing. 
 9.3 MediciNova’s Proprietary Rights. Except as set forth in the final sentence of Section 9.2, MediciNova
has granted no license, express or implied, to Hospira to use MediciNova’s IP, proprietary know-how or other proprietary rights. All MediciNova IP transferred to Hospira hereunder and Project IP developed hereunder shall be deemed to be the
Confidential Information of MediciNova and subject to the non-use and non-disclosure obligations described in Article 11. 
 Article
10     TERM AND TERMINATION 
 10.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated as provided below, shall expire at the end of the tenth (10th) Commercialization Year thereafter (the “Initial Term”). Unless otherwise terminated in accordance with this Article 10, this Agreement shall be
automatically extended for additional terms of two (2) years each (each, a “Renewal Term”) and may be terminated anytime after the Initial Term by either party providing the other with at least twelve (12) months
prior written notice of termination. 
  

 -21- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 10.2 Termination of the Project. The parties may terminate the Project upon
written agreement, which written agreement shall not be unreasonably withheld for a period of more than [***] from notice, if a party determines in good faith that the development of the Products is not technically feasible despite each party’s
commercially reasonable efforts to develop Products for commercial sale. If the Project is terminated, Hospira shall advise MediciNova of Hospira’s actual development costs of the Project incurred prior to such termination. MediciNova shall pay
Hospira for all reasonable and documented development costs incurred to the date the termination notice is received or the prorated milestone that is applicable. 
 10.3 Failure to Obtain Regulatory Approval. Either party may terminate this Agreement by giving to the other party two
(2) months’ prior written notice if the Product has not received regulatory approval for commercial sale by [***]. 
 10.4 General Termination Rights. Either party may terminate this Agreement as follows: 
 (a)
immediately by providing written notice upon the bankruptcy or the insolvency of the other party; or 
 (b) by giving to the
other party sixty (60) days’ prior written notice upon the breach of any warranty or any other material provision of this Agreement by the other party if the breach is not cured within sixty (60) days after written notice thereof to
the party in default. 
 10.5 MediciNova Termination. MediciNova may terminate this Agreement by giving Hospira
[***] prior written notice if MediciNova decides to cease development or commercialization of Product. 
 10.6 Hospira
Termination. If in any [***] consecutive Commercialization Years MediciNova (i) waives some or all of Hospira’s manufacturing and delivery obligations and pays Hospira for Product instead of taking delivery of some or all the
Product constituting its relevant Minimum Purchase Requirement as permitted in Section 6.8 hereof and (ii) the waiver covers Product equal to more than [***] of MediciNova’s total Minimum Purchase Requirement for each of the
relevant [***] consecutive Commercialization Years, then Hospira may terminate this Agreement upon [***] prior written notice to MediciNova. 
  

 -22- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 10.7 Accrued Payment Obligations. Termination of this Agreement shall not
relieve either Party of any liability which has accrued prior to the effective date of such termination, nor prejudice either Party’s right to obtain performance of any obligation provided for in this Agreement, which by its express terms or
context survives termination, provided that (i) with respect to a termination pursuant to Section 10.3, MediciNova shall be obligated to purchase all Product ordered pursuant to Firm Purchase Orders, assuming that production of
Product will be wound down promptly and ceased as soon as reasonably practicable by Hospira, (ii) with respect to a termination by MediciNova pursuant to Section 10.4, MediciNova shall not be obligated to purchase any further
Product, but may it may require Hospira to fill all outstanding Firm Purchase Orders, as well as provide to MediciNova enough Product to meet some or all of its Product Supply Commitment as such commitment exists on the date of termination,
(iii) with respect to a termination by Hospira pursuant to Section 10.4, MediciNova shall be required to purchase all outstanding Firm Purchase Orders, (iv) with respect to a termination by MediciNova pursuant to
Section 10.5, MediciNova shall be obligated to purchase all Product ordered pursuant to Firm Purchase Orders, assuming that production of Product will be wound down promptly and ceased as soon as reasonably practicable by Hospira and
(vi) with respect to a termination by Hospira pursuant to Section 10.6, MediciNova shall be required to purchase all Product ordered pursuant to Firm Purchase Orders, assuming that production of Product will be wound down promptly
and ceased as soon as reasonably practicable by Hospira. Upon termination pursuant to this Article 10, unless termination is by MediciNova pursuant to Section 10.4, MediciNova shall reimburse Hospira for Hospira’s cost of all
supplies purchased and on hand or on order, if such supplies were ordered by Hospira based on Firm Purchase Orders or MediciNova’s estimates of its requirements of the Products, and such supplies cannot be reasonably used by Hospira for other
purposes, provided reimbursement shall not be for more than three (3) months of supplies specific to Products, or otherwise cancelled at no cost by Hospira. Hospira shall invoice MediciNova for all amounts due hereunder. Payment shall be made
pursuant to Section 5.9. 
 10.8 Return of Inventory. In the event of any termination, Hospira shall
return any remaining inventory of API and Products to MediciNova at MediciNova’s expense, unless such termination shall have been as a result of a breach of this Agreement by Hospira, in which case such inventory shall be returned at
Hospira’s expense. 
 10.9 Return of Equipment. Upon expiry or termination of this Agreement, Hospira will
ship all dedicated equipment purchased by Hospira in accordance with Section 5.6 to a location specified by MediciNova at MediciNova’s cost and expense. In the event MediciNova does not wish to take possession of such dedicated
equipment, Hospira will dispose of such equipment. 
 10.10 Files and Records. Upon the expiration or
termination of this Agreement, Hospira shall promptly make available to MediciNova copies of all manufacturing and batch records relating to the Product and shall store the originals or electronic copies of such documents and records according to
cGMPs in accordance with Hospira’s internal quality procedures and Applicable Laws. 
  

 -23- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 10.11 Survival. Expiration or early termination of this Agreement shall not
relieve either party of any obligations that it may have incurred prior to expiration or early termination and all covenants and agreements contained in this Agreement, which by their terms or context are intended to survive, will continue in full
force and effect, including without limitation, Sections 5.5(c), 7.3, 7.4, 7.6, 7.7, 8, 9, 10.7-10.11, 11, and 12 (to the extent relevant). 
 Article 11     CONFIDENTIAL INFORMATION 
 11.1 Nondisclosure. It is contemplated that in the course of the performance of this Agreement each party may, from time to
time, disclose Confidential Information to the other. Hospira agrees that, except as expressly provided herein, it shall not disclose Confidential Information received from MediciNova, and shall not use Confidential Information disclosed to it by
MediciNova, for any purpose other than to fulfill Hospira’s obligations hereunder. MediciNova agrees that, except as expressly provided herein, it shall not disclose Confidential Information received from Hospira, and shall not use Confidential
Information disclosed to it by Hospira, for any purpose other than to fulfill MediciNova’s obligations hereunder. MediciNova shall have the right to share the terms of this Agreement and this Agreement with its current and potential
collaborators, partners, and investors who are obligated to keep its terms confidential. 
 11.2 Exceptions to Duty of
Nondisclosure. Notwithstanding the above, nothing contained in this Agreement shall preclude MediciNova from utilizing Confidential Information as may be necessary in prosecuting patent rights related to Product, obtaining governmental
marketing approvals, or complying with other governmental laws and regulations or court orders (provided that the party disclosing such information uses reasonable efforts to seek confidential treatment of such information. The obligations of the
parties relating to Confidential Information shall expire ten (10) years after the termination of this Agreement. In addition, if either party, based on the advice of its counsel, determines that this Agreement, or any of the other documents
executed in connection herewith, must be filed with the Securities and Exchange Commission (“SEC”), then such party shall have the right to file this Agreement (or such other documents) with the SEC, provided that such
party notifies the other party reasonably in advance of such filing and uses commercially reasonable efforts to obtain confidential treatment of the material terms and conditions of this Agreement (consistent with Applicable Law). 
 11.3 Return of Confidential Information. Upon termination of this Agreement, the receiving party shall, if so requested by
the disclosing party, promptly return to the disclosing party the originals and all copies of any Confidential Information (including all extracts, summaries and derivatives thereof) then in the receiving party’s possession or under the
receiving party’s control. Notwithstanding the foregoing, the receiving party may retain one (1) copy of such Confidential Information for legal archival purposes, provided that such copy shall be kept confidential after the termination or
expiration of this Agreement. 
  

 -24- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 11.4 Handling and Reconstruction of and Access to Confidential Information.
Each party will maintain the originals or electronic copies of all documents containing disclosing party’s Confidential Information according to its own internal quality procedures, cGMP and Applicable Laws. Accordingly, each party will ensure
that such procedures incorporate and maintain appropriate safety and facility procedures, data security procedures and other safeguards against the destruction, loss, or alteration of the disclosing party’s Confidential Information in the
possession of the receiving party, including procedures for the recovery and reconstruction of lost Confidential Information. At no time will the receiving party store or hold the disclosing party’s Confidential Information in a form or manner
not promptly accessible to the disclosing. Each party agrees that it will not withhold from the other any Confidential Information as a means of resolving a dispute. 
 11.5 Public Announcements. Neither party shall make any public announcement concerning the transactions contemplated herein,
or make any public statement which includes the name of the other party or any of its Affiliates, or otherwise use the name of the other party or any of its Affiliates in any public statement or document without the prior written consent of the
other party, except as may be required by law, regulation, including SEC regulation, or judicial order, in which case the party required to make the public announcement or public statement shall use commercially reasonable efforts to obtain the
approval of the other party as to form, nature and extent of the public announcement or public statement prior to issuing the same. 
 11.6 Injunctive Relief. In the event of a breach or threatened breach by a party of any provision of this Article, the other Party shall be authorized and entitled to obtain from any court of competent jurisdiction equitable
relief, whether preliminary or permanent, in addition to any other rights or remedies to which such party may be entitled in law or equity. 
 Article 12     MISCELLANEOUS 
 12.1 Force Majeure and Failure of
Suppliers. 
 (a) Excusable Delay. Any delay in the performance of any of the duties or obligations of
either party hereto (except the payment of money) shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by
or is the result of any acts of God, acts of a public enemy or other terrorist acts, insurrections, riots, embargoes, labor disputes, including strikes, lockouts, job actions, boycotts, fires, explosions, floods, shortages of material or energy, or
other unforeseeable causes beyond the control and without the fault or negligence of the party so affected. The effected party shall give prompt notice 

  

 -25- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 
to the other party of such cause and a good faith estimate of the continuing effect of the force majeure condition and duration of the affected party’s
nonperformance, and shall take promptly whatever reasonable steps are necessary or appropriate to relieve the effect of such cause(s) as rapidly as possible. Subject to the provisions of Section 12.1(b), if a force majeure prevents
Hospira from manufacturing Products ordered by MediciNova hereunder for more than six (6) months, then MediciNova may terminate this Agreement immediately without further obligation to Hospira. 
 (b) Transfer of Production. If Hospira becomes subject to a force majeure event which prevents or substantially interferes
with manufacture of the Products at Hospira’s manufacturing facility, the parties shall mutually agree on implementation of an agreed-upon action plan to transfer production of the Products to another Hospira facility. The parties shall, after
the execution of this Agreement and at the request of either party, meet to discuss and define such an action plan. 
 (c) Failure of Suppliers. The parties understand and agree that
MediciNova will approve in advance, which approval shall not be unreasonably withheld, the suppliers chosen by Hospira to supply the excipient and (excepting the components of the ADD-Vantage®
 Drug Delivery System) the primary container packaging component. MediciNova shall have no liability to Hospira for such suppliers nor shall MediciNova be deemed to be in breach of this Agreement if a supplier is unable to supply excipients
and components to Hospira. Hospira shall be fully responsible for the timely and complete performance of all the suppliers it utilizes in connection herewith. 
  

 -26- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 12.2 Notices. All notices hereunder shall be delivered as follows:
(a) personally; (b) by facsimile and confirmed by first class mail (postage prepaid); (c) by registered or certified mail (postage prepaid); or (d) by overnight courier service, to the following addresses of the respective
parties: 
  

			
	If to MediciNova:	  	With a copy to:
		
	 4350 La Jolla Village Drive
 Suite 950
 San Diego, California 92122
 Attention: Richard Gammans, Ph.D.
 Telephone: (858) 622-9750
 Facsimile: (858) 373-7000
	  	 Blaine Templeman
 Sheppard, Mullin, Richter &
Hampton LLP
 30 Rockefeller Plaza, Suite 2400
 New York, New York
10112
 Telephone: (212) 332-3854
 Facsimile: (212)
332-1204

		
	If to Hospira:	  	With copy to:
		
	 Hospira, Inc.
 275 North Field Drive
 Lake Forest, Illinois 60045
 Attn: Vice President & General Manager

 Contract Manufacturing
 Facsimile:
(224) 212-3210
	  	 Hospira, Inc.
 Attention: General Counsel

Building H1; Department NLEG
 275 N. Field Drive
 Lake Forest, Illinois 60045
 Fax: (224) 212-2086

 Notices shall be effective upon receipt if personally delivered or delivered by facsimile and
confirmed by first class mail, on the fifth business day following the date of registered or certified mailing or on the first business day following the date of or delivery to the overnight courier. A party may change its address listed above by
written notice to the other party. 
 12.3 Choice of Law/Venue/Jurisdiction. This Agreement shall be construed,
interpreted and governed by the laws of the State of New York, excluding its choice of law provisions. The United Nations Convention on the International Sale of Goods is hereby expressly excluded. 
 12.4 Collaborations. Notwithstanding anything to the contrary herein, Hospira agrees that MediciNova shall have the right to
enter into partnerships, collaborations or alliances with third parties who may engage in joint (with MediciNova) or unilateral development, marketing and promoting of Product (each, a “Collaboration Development Partner”).

 12.5 Assignment. Neither party shall assign this Agreement nor any part thereof without the prior written
consent of the other party; provided, however: (a) either party may assign this Agreement to one of its wholly-owned subsidiaries or its parent corporation without such consent; (b) either party, without such consent, may assign this
Agreement in connection with the transfer, sale or divestiture of substantially all of its business to which this Agreement pertains or in the event of its merger or consolidation with another company; and (c) MediciNova may assign this
Agreement to a Collaboration Development Partner. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve any party of its responsibility hereunder. 
  

 -27- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 12.6 Entire Agreement. This Agreement, together with the Exhibits
referenced and incorporated herein, constitute the entire agreement between the parties concerning the subject matter hereof and supersede all written or oral prior agreements or understandings with respect thereto. The LOI has expired as of the
Effective Date. 
 12.7 Severability. This Agreement is subject to the restrictions, limitations, terms and
conditions of all applicable governmental regulations, approvals and clearances. If any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never
been contained herein. 
 12.8 Waiver-Modification of Agreement. No waiver or modification of any of the terms
of this Agreement shall be valid unless in writing and signed by authorized representatives of both parties. Failure by either party to enforce any such rights under this Agreement shall not be construed as a waiver of such rights, nor shall a
waiver by either party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
 12.9 Hospira Insurance. Hospira will procure and maintain, at its own expense, for the duration of the Agreement, and for five (5) years thereafter if written on a claims made or occurrence reported form, the types of
insurance specified below with carriers rated A-:VII or better with A. M. Best or like rating agencies: 
 (a) Workers’
Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of MediciNova; 
 (b) Employer’s Liability with a limit of liability in an amount of not less than [***]; 
 (c) Commercial
General Liability including premises operations, products & completed operations, blanket contractual liability, personal injury and advertising injury including fire legal liability for bodily injury and property damage in an amount not
less than [***] per occurrence and [***] in the aggregate; 
 (d) Commercial Automobile Liability for owned, hired and
non-owned motor vehicles with a combined single limit in an amount not less than [***] each occurrence; 
  

 -28- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (e) Excess Liability including products liability with a combined single limit in an
amount of not less than [***] per occurrence and in the aggregate; 
 (f) Commercial Crime or Fidelity Bond in an amount of
not less than [***] per occurrence and in the aggregate. 
 Hospira shall include MediciNova as additional insured with respect to such
policies. Prior to commencement of services, and annually thereafter, Hospira shall furnish to MediciNova certificates of insurance evidencing the insurance coverages stated above and shall require at least thirty (30) days written notice to
MediciNova prior to any cancellation, non-renewal or material change in said coverage. In the case of cancellation, non-renewal or material change in said coverage, Hospira shall promptly provide to MediciNova a new certificate of insurance
evidencing that the coverage meets the requirements in this Section 12.9. Hospira agrees that its insurance shall act as primary and noncontributory from any other valid and collectible insurance maintained by the other party. Hospira
may, at its option, satisfy, in whole or in part, its obligation under this Section 12.9 through its self-insurance program, provided that Hospira has the financial wherewithal to support such self insurance. 
 12.10 MediciNova Insurance. MediciNova will procure and maintain, at its own expense, for the duration of the Agreement, and
for five (5) years thereafter if written on a claim made or occurrence reported form, the types of insurance specified below with carriers rated A- VII or better with A. M. Best or like rating agencies: 
 (a) Workers’ Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of
Hospira; 
 (b) Employer’s Liability with a limit of liability in an amount of not less than [***]; 
 (c) Commercial General Liability including premises operations, product liability, products & completed operations, personal
injury and advertising injury including fire legal liability for bodily injury and property damage: (i) during the Product development stage, in an amount not less than [***] per occurrence and not less than [***] in the aggregate; and
(ii) during commercialization of the Products in the Territory, in an amount not less than [***] per occurrence and not less than [***] in the aggregate; 
 (d) Commercial Automobile Liability for owned, hired and non-owned motor vehicles with a combined single limit in an amount not less than
[***] each occurrence; 
 (e) Commercial Crime or Fidelity Bond in an amount of not less than [***] per occurrence and in the
aggregate including an endorsement for third party liability without the requirement of a conviction. 
  

 -29- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 (f) Property in Transit insurance in an amount not less than [***]. 
 Hospira shall be an additional insured with respect to such policies. Prior to commencement of services, and annually thereafter,
MediciNova shall furnish Hospira certificates of insurance evidencing the insurance coverages stated above and shall require at least thirty (30) days written notice to Hospira prior to any cancellation, non-renewal or material change in said
coverage. In the case of cancellation, non-renewal or material change in said coverage, MediciNova shall promptly provide to Hospira a new certificate of insurance evidencing that the coverage meets the requirements in this
Section 12.10. MediciNova agrees that its insurance shall act as primary and noncontributory from any other valid and collectible insurance maintained by the other party. MediciNova may, at its option, satisfy, in whole or in part, its
obligation under this Section 12.10 through its self-insurance program, provided that MediciNova has the financial wherewithal to support such self insurance. 
 12.11 Exhibits. All Exhibits referred to herein are hereby incorporated by reference. 
 12.12 Further Actions. The Parties shall duly execute and deliver, or cause to be duly executed and delivered, such further
instruments, and to do and cause to be done such further acts, that may be necessary to carry out the provisions and purposes of this Agreement, notwithstanding any expiration or termination of this Agreement. 
 12.13 Subcontracting. Hospira shall not assign, subcontract or delegate any of its rights or obligations under this
Agreement without the express prior written authorization of MediciNova. Hospira shall cause any such authorized subcontractor to be subject by contract to the same restrictions, exceptions, obligations, reports, termination provisions and other
provisions contained in this Agreement as are applicable to Hospira. Hospira shall remain primarily obligated for all acts and omissions of any of its subcontractors as if Hospira had performed the subcontracted obligations itself, and shall
guarantee the performance of the same. 
 12.14 Successors; Assigns. This Agreement shall be binding upon and
inure to the benefit of the Parties hereto and each of their respective successors and permitted assigns. 
 12.15
Independent Contractor. This Agreement shall not be deemed to create any partnership, joint venture, or agency relationship between the Parties. Each Party shall act hereunder as an independent contractor, and its agents and employees
shall have no right or authority under this Agreement to assume or create any obligation on behalf of, or in the name of, the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party, and all costs and
obligations incurred by reason of any such employment shall be for the account and expense of such Party. 
  

 -30- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 12.16 Counterparts. This Agreement may be executed by original or facsimile
signature in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 12.17 Headings. The headings used in this Agreement are for convenience only and are not a part of this Agreement.

 IN WITNESS WHEREOF, the parties intending to be bound by the terms and
conditions hereof have caused this Agreement to be signed by their duly authorized representatives as of the date first above written. 
  

									
	HOSPIRA WORLDWIDE, INC.	 		 	MEDICINOVA, INC.
					
	By:	 	/s/ Anthony N. Cacich	 		 	By:	 	/s/ Richard E. Gammons
	Name:	 	Anthony N. Cacich	 		 	Name:	 	Richard E. Gammons
	Title:	 	Vice President & General Manager,	 		 	Title:	 	Chief Development Officer
		 	Contract Manufacturing	 		 		 	

  

 -31- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 1.2 
 API Specifications 
 [***] 
  

 -32- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 1.19 
 Product Specifications 
 [***] 
  

 -33- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 2.1 
 Development Fees Structure 
 [***] 
  

 -34- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 3.1 
 Payment Schedule 
 [***] 
  

 -35- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 3.2 
 FTE Rates 
 Hospira shall use the following FTE Rates in calculating additional costs for Change
Orders and/or additional work: 
 [***] 
  

 -36- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 5.8 
 Product Prices 
 [***] 
  

 -37- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 7.1 
 Product Test Methods 
 The parties will adopt and implement appropriate Product testing and release
methods in accordance with the Quality Agreement to be attached to this Agreement as Exhibit 7.2. Upon adoption and implementation, such testing and release methods will be appended to this Exhibit 7.1 and will be made an integral part
of this Agreement. 
  

 -38- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 7.2 
 Form of Quality Agreement 
 [***] 
  

 -39- 
  

 Certain information in this exhibit, marked by brackets and asterisks [***], has been omitted and will be filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]